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During mammalian embryogenesis the development of cell lineages and multiple organ 
systems are tightly associated with the finely tuned and orchestrated functions of transcription 
factors (Adamson & Gardner, 1979). The resulting differential gene expression is the basis of 
tissue specific protein production, which enables conduction of diverse functions of the 
organism constructed by myriad of cells harbouring the same genetic information (Adamson 
& Gardner, 1979). Epigenetic factors are crucial in modulating these mechanisms via multiple 
interacting factors and regulatory networks (Artyomov et al., 2010). In my thesis, I determined 
the connections between a polycomb group epigenetic factor RING1 and YY1 binding protein 
(RYBP) also called as Death effector domain-associated factor (DEDAF) and cardiac 
transcription factor Pleiomorphic adenoma gene like 1 (PLAGL1) in the regulation of cardiac 
differentiation using in vitro model system applying mouse embryonic stem (ES) cells. 
 
1.1 Stem cells as model systems of developmental process and congenital heart disorders 
During embryogenesis, the inner cell mass (ICM) of the blastocyst contains the pluripotent ES 
cells that have the capability to differentiate towards all lineages of the body (Marikawa & 
Alarcón, 2009). These cells undergo several cellular events leading towards organogenesis 
(Sasai et al., 2012). ES cells have distinctive features such as- (i) they can divide perpetually 
and self-renew by maintaining the pluripotency of the cells even in cultures; (ii) by changing 
the culture conditions, they can be differentiated into special cell types such as muscle cells, 
nerve cells etc. (Zakrzewski et al., 2019). ES cells also have the ability to the formation of germ 
layers when re-introduced into the early-stage embryo (Gardner & Brook, 1997). Due to these 
abilities, stem cells based in vitro differentiation systems have been widely used as excellent 
model systems to recapitulate the early events of organ development and related disease 
conditions (Keller, 1995; Levinson & Benvenisty, 1995).  
Congenital heart disorders (CHDs) occur due to the structural and functional anomalies during 
heart development (Mckusick, 1964; McCulley & Black, 2012). CHDs are commonly caused 
due to the atrial septal defects, ventricular septal defects, atrioventricular canal defect and valve 
stenosis which often led to serious conditions of contractility disorders. The loss of function of 
several transcription factors have been demonstrated to contribute to CHD conditions both 
using in vivo mouse and in vitro model systems. Improper expression of key cardiac 
transcription factors such as the NK2 homeobox 5 (NKX2-5), Myocyte enhancer factor 2c 
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(MEF2C) and T-box 5 (TBX5) caused serious malformations of the developing heart and 
contractility functions (McCulley & Black, 2012; Weerd et al., 2011). The effect of Plagl1 
mutation is also implicated to heart malformations and CHD conditions as the Plagl1 
heterozygous mutant mice formed atrial and ventricular septal defects (Yuasa et al., 2010). 
Stem cells based in vitro cardiac differentiation methods offer a unique platform to model CHD 
conditions, to dissect and study the molecular mechanisms involved in regulating contractility 
as well as the underlying role of specific transcription factors that might also potentiate to future 
therapeutics (Moretti et al., 2013). 
1.2 Process of mouse embryonic cardiac differentiation 
Since ES cell based in vitro cardiac differentiation system can mimic the in vivo heart formation 
morphologically, functionally and electrophysiologically (Hescheler et al., 1997; Fijnvandraat 
et al., 2003) the different stages of in vitro cardiomyogenesis can be related to the knowledge 
gained from the plethora of studies carried in vivo. A series of cardiac markers identified in 
vivo are generally used to characterize the differentiation state of in vitro cultures. 
Mammalian cardiac system is one of the first functional organ that develops in an early embryo 
(Savolainen et al., 2009). The contraction of the embryonic heart and initiation of the 
rudimentary circulatory system is essential for mammalian embryonic development. The heart 
originates from the embryonic mesoderm that further differentiates into mesothelium, 
endothelium and myocardium (DeRuiter et al., 1992; Yutzey et al., 1995). Mesothelial 
pericardium forms the outer lining of the heart (Madani & Golts, 2014). The inner lining of the 
heart as well as the lymphatic and blood vessels, develop from the endothelium. The early 
multipotent progenitor cells (MPCs) give rise to the atrial and ventricular cell types, fibroblast 
cells, endocardial and epicardial cells, cells of the conductive system (sinoatrial, 
atrioventricular, Purkinje fiber cells), the smooth muscle cells of the aorta, artery and the 
autonomic nerve cells (Weerd et al., 2011). The cardiac sarcomere is the critical unit of cardiac 
muscle fibres that functions in contraction (Sweeney & Hammers, 2018). The formation of all 
these cell types is crucial in maintaining the structure and functions of the developing heart. 
1.3 Markers of cardiac differentiation 
Series of mouse knockouts and in vitro cell culture models have shown the precise timeline 
and exact spatiotemporal expression of key cardiac transcription factors (Table 1). Mesodermal 
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lineage specification is guided by the exit of pluripotency and induction of the T-box 
transcription factors Brachyury (T) and Eomesodermin (EOMES) by graded Transforming 
growth factor beta 1 (TGF-β)/NODAL and the canonical Wingless-type MMTV integration 
site family (WNT) signalling (Figure 1) (Arnold et al., 2009; Watabe & Miyazono, 2009; Tosic 
et al., 2019). T and Eomes are expressed from the early gastrulation stage embryos from E6 in 
the primitive streak of the early mouse embryo (Wilkinson et al., 1990; Chesley, 1935; Russ et 
al., 2000; Nowotschin et al., 2013). The T homozygous mice showed serious implications in 
the morphogenesis of mesoderm derived structures such as the heart (Table 1) (Yanagisawa et 
al., 1981). Both Eomes and T can induce the expression of the Mesoderm posterior 1 (Mesp1) 
which is expressed in the developing heart tube and specifies cardiovascular lineage (Saga et 
al., 1999; David et al., 2011; Guo et al., 2018; Ameele et al., 2012). The expression of Mesp1 
defines the earliest step of cardiac lineage commitment (Figure 1) (Saga et al., 2000; Lescroart 
et al., 2018). MESP1 can target and induce the expression of several cardiac transcription 
factors that specifies progenitor formation (Bondue et al., 2008; Soibam et al., 2015) such as 
the Kinase insert domain protein receptor (Kdr also called as Flk1), multipotent cardiac 
progenitor marker Islet-1 (Isl1) (Cai et al., 2003 ; Moretti et al., 2006) the early cardiac 
progenitor markers which implicates formation of first and second heart fields Nkx2.5, Mef2c 
and cardiac endothelial progenitor marker GATA binding protein 4 (Gata4) (Christoforou et 
al., 2008; Lyons et al., 1995; Tanaka et al., 1999; Terada et al., 2011) (Figure 1). The non-
canonical WNT pathway and NODAL are determined to function upstream to the cardiac 
progenitor formation during the first and second heart field derivation (Figure 1) (Brade et al., 
2006; Gessert & Kühl, 2010; Kamps, 2016). Ascorbic acid is shown to promote cardiac 
differentiation through the induction of BMP, SMAD1 signalling and inhibition of the TGF-β 
signalling (Ivanyuk et al., 2015; Perino et al., 2017). Ascorbic acid is also determined as a 
potent inducer of several cardiac progenitor expression such as Nkx2-5, Mef2c and Gata4 
(Figure 1) (Takahashi et al., 2003; Lin et al., 1997; Kamps, 2016; Molkentin et al., 1997. During 
the cardiac progenitor formation, the expression of T-Box proteins T-Box 3 (Tbx3), T-Box 5 
(Tbx5) and T-Box 18 (Tbx18) are required for the generation of pacemaker cells that function 
in the conduction system of the heart (Mori et al., 2006). As a result of these finely tuned events 
governed by series of key transcription factors, the developing heart starts beating as early as 




Table 1: Mutant phenotypes for key cardiac genes 
Key cardiac genes used in this study are enlisted in the rows of the table. The corresponding 
nature of the analysed mutations, lethality time, the cardiac phenotypes and the reference of 
the studies are presented in the indicating columns of the table. Lethality time of mutant mice 
corresponds to the stage of embryonic heart development when the effect of the loss of the 
respective markers are implicated, and the represented alterations specify the significance of 






Gene Name Mutation type Mutation at Lethality time Cardiac Phenotype Source
T complete null ND E10 Improper notochord formation Chesley., 1935
Eomes complete null exon 2 & intron 2 E6.0 Improper primitive streak formation Russ et al., 2000
MesP1 complete null exon 1 & 2 E10.5
Altered heart morphology, two abnormally 
symmetrical heart tubes and the beat periodicity was 
not coordinated between one tube and the other.
Saga., 1999
Isl1 hypomorph exon 3- second LIM 
domain
E8.5- E11.5 No outflow tract, no right ventricule and formation 
of hypoplastic atria 
Cai et al., 2003
Nkx2-5 hypomorph exon 2 E9 No looping, lack of endocardial cushion 
&trabeculae
Lyons et al., 1995
Gata4
hypomorph (only 2 
ZNF binding 
domains deleted)
exon 3 & 4 E10.5 No ventral folding, position of developing heart is 
lateral & dorsal to the neural tube.
Molkentin et al., 1997
Mef2c complete null exon 2 E10.5
Pericardial effusion, very slowly beating, formation 
of hypoplastic ventricular chamber with no looping 
of cardiac tube
Lin et al., 1997
Tbx-5 hypomorph exon 3 E10.5
Dilated heart atrium, formation of hypoplastic left 
ventricle and bifurcated atrial tube Mori et al., 2006
Plagl1 complete null intron 3 E10.5 Atrium Septum defect, ventricular septum defect 
and formation of thin ventricular wall
Yuasa et al., 2010
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Figure 1: Schematic illustration of the markers involved in the stages of in vitro cardiac 
differentiation (modified from Kamps, 2016)  
Factors that influence the progression of the five stages of cardiomyocyte differentiation: 
mesoderm formation (grey background), cardiac mesoderm specification (beige background), 
cardiac progenitor formation (pale yellow background), cardiomyocyte generation (rose 
background) and cardiomyocyte maturation (peach colour). Transcription factors associated 
with each of the six cell types during cardiomyocyte differentiation are presented below. The 
relating time points of in vitro cardiac differentiation is presented at the bottom. Signalling 
pathways and chemical inducers that guide the expression of the described transcription 
factors are highlighted in boxes. Pointed arrows (in black) indicates positive regulation and 
bar headed arrows (in red) indicates inhibition of differentiation. Abbreviations: ES- 
embryonic stem, EB- embryoid body, d- day, LIF- Leukaemia inhibitory factor. 
1.4 In vitro cardiac differentiation methods 
Over the years, several in vitro differentiation methods have been described for the 
differentiation of ES cells to form contractile cardiac cultures. ES cells cultured with stromal 
cells can differentiate to functional cardiomyocytes (CMCs) by (i) the formation of embryoid 
bodies (EB’s), (ii) by monolayer formation in Matrigel or by, (iii) generation of cardiac 
organoids (Figure 2). 
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(i) The EB based methods (Evans & Kaufman, 1981) of cardiac differentiation are 
more robust and simpler, therefore they are widely used for cardiac differentiation 
using mouse ES cells. These methods generally start with the EB formation step by 
either the hanging drop (HD) method, suspension cultures or employing specific 
culture vessels such as the slow turning lateral vessel bioreactor (STLV) 
(Rungarunlert et al., 2013). As the EBs cultured in HDs and STLVs are more 
uniform and evenly sized, these methods are preferred over the suspension culture 
method for cardiac differentiation in which the formed EBs are irregularly shaped 
and diverse in their size (Wang & Yang, 2008). The EBs are cultured in humidified 
conditions for 48 hours, plated out and cultured further to form beating CMCs with 
no chemical inducers (Wang & Yang, 2008). Some EB based methods for cardiac 
differentiation also use inducing factors of signalling pathways that influence 
cardiac lineage commitment such as basic fibroblast growth factor-2 (bFGF-2) 
(Kawai et al., 2004).  
(ii) In the monolayer system of ES cells are cultured along with supporting cell layers 
(e.g., mouse embryonic fibroblasts (MEF) in monolayers seeded on matrigel or 
surface treated tissue culture plates) (Batalov & Feinberg, 2015). The cells are then 
induced with growth factors such as basic fibroblast growth factor (bFGF) and 
ascorbic acid (Kokkinopoulos et al., 2016) to generate beating CMCs. Another 
method depicts the induction of BMP signalling pathway for the differentiation of 
monolayer ES cells. Induction of these growth factors promote the signalling for 
cardiac lineage commitment and CMCs formation (Zhang et al., 2012). 
(iii) Another previously used method involves co-culture of ES cells with isolated 
mesenchymal cells (Pucéat, 2008) or endoderm like cell (END2 cells) which 
resulted in contractile CMCs (Mummery et al., 2012).  
(iv) In the last few years, organoid culture has become the new trend for in vitro 
differentiation of stem cells as they replicate key spaciotemporal features of the in 
vivo organ. In these methods, ES cells are let to form EBs and further cultured in 
media containing FGF4, BMP and ascorbic acid for several days to form beating 
cardiac organoids (cardioids) with chamber like specifications (Lee et al., 2020). 
Due to the reproducibility and the simplicity of the technique, the hanging drop method of EB 
generation was employed in this thesis study and no specific inducers were utilized (described 
in detail in Methods 3.1.2). 
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Figure 2: In vitro cardiac differentiation methods 
CMCs can be differentiated in vitro from ES cells through (EB formation by (1) Hanging drops 
or (2) suspension culture, (3) monolayer culture or (4) formation of cardioids. Abbreviations: 
mES cells: Mouse embryonic stem cells, EB: Embryoid body, CMCs: Cardiomyocytes. 
1.5 Utilisation of luciferase reporter system to study gene regulation 
Luciferase reporter systems are widely used for studying promoter activities influenced by the 
regulatory functions of transcription factors which also relate to distinct cellular responses. 
This system is based on the activity of a bioluminescent protein Firefly, which produces light 
when reacted with a substrate D-luciferin (Figure 3) (Marques & Da Silva, 2009). This system 
is mainly exhausted to establish a functional relationship between the presence and 
concentration of specific regulatory proteins and the level of transcriptional activation (Firefly 
reporter) of the promoter analysed. The promoter of interest is cloned upstream to the firefly 
coding region; therefore, it effectively controls its expression. In a typical experimental assay, 
the cloned promoter construct is subjected to the influence of presumptive regulatory proteins 
upon overexpression (Figure 3). The relative expression level of the resulting firefly reporter 
is directly proportional to the activation/repression levels of the monitored promoter (Fan & 
Wood, 2007). Since Firefly protein is not natively present in mammalian cells, it does not have 
any detrimental effect on the endogenous cellular process (Keller et al., 1987), thereby this 
system provides reliable and reproducible opportunity to study regulatory activities of specific 
transcription factors. 











Although luciferase reporter systems do not determine whether a regulatory protein directly 
interacts with a putative promoter region, they can be used to establish a functional connection 
between the protein and the amount of promoter activity induced by the protein (Carter & 
Shieh, 2015). Many proteins could indirectly affect transcription of the examined promoter by 
activating or repressing other regulatory proteins, assembly of different protein complexes, or 
signalling mechanisms that in return can affect the regulation of the promoter. 
To distinguish between direct regulators and secondary effects, during my PhD studies I used 
luciferase reporter systems and firefly reporter constructs to molecularly analyse the detailed 
regulation of Plagl1 promoters. I made several mutations of the predicted transcriptional 
binding sites and coupled these experiments with Chromatin immunoprecipitation (ChIP) 
assays (details in methods 3.1.5, 3.2.2, 3.2.4 and 3.4.5) to identify the molecular mechanism 
by which RYBP could mediate its effects during cardiac differentiation. 
 
Figure 3: Promoter regulation analysis using luciferase reporter system  
Schematic representation of the luciferase reporter system. Promoter of interest is cloned 
upstream of the firefly coding region. Adding a specific substrate, D-luciferin, the illumination 
of the firefly protein is triggered and detected using a luminometer. The amount of 
bioluminescent signal generated by firefly is directly proportional to the activity of the 
promoter. Abbreviations: RNA Pol-RNA Polymerase, TF-Transcription factor. 
 
1.6 Polycomb repressive complexes and their regulatory roles in mammalian 
development 
Epigenetic maintenance of differential gene expression is essential for proper differentiation 













group protein complexes orchestrate these mechanisms by regulating genes as early as the 
trophoblast differentiation of a developing embryo (Schuettengruber et al., 2007; Kuroda et al., 
2020). Polycomb group proteins (PcG) are a family of epigenetic silencers implicated in growth 
and development (Gould, 1997); cancer progression and suppression (Laugesen et al., 2016); 
stem cell maintenance and regulation (Aloia et al., 2013) and X-chromosome inactivation 
(Simon & Kingston, 2013). PcG proteins form two principal complexes, named Polycomb 
repressive complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2) (Figure 4A) (Vidal, 
2009). Each complex has constant and variable protein subunits that lead to distinctive cell and 
tissue specific regulation (Gao et al., 2012). The PRC2 complex is a highly conserved multi-
subunit protein complex that consists of Enhancer of zeste subunit 1/2 (EZH1/2), Suppressor 
of zeste (SUZ12), Embryonic ectoderm development (EED) and Retinoblastoma binding 
protein 4/7 (RBBP4/7) which form the minimum core of the complex (Czermin et al., 2002; 
Kuzmichev et al., 2002; Müller et al., 2002). The SET domain containing EZH1/2 factor is the 
catalytic subunit of the complex which specifically deposits the trimethyl mark on lysine 27 of 
histone 3 (H3K27me3), a major chromatin repressive modification (Figure 4A) (Shen et al., 
2008). SUZ12 consists of the ZnB-Zn domain that is able to bind to several interacting partners 
which provides target specificity to the PRC2 complex (Chen et al., 2018). RBBP4/7 factors 
are dispensable for the catalytic activity of the complex (Cao & Zhang, 2004; Ketel et al., 
2005). EED functions in the interaction and recruitment of the chromobox domain containing 
transcription factors (CBX) containing PRC1 complex (also called as the canonical PRC1s) to 
the H3K27me3 modified loci for further enhancement of the PRC1 mediated mono-
ubiquitination mark on lysine 119 of histone 2a (H2AK119ub1) an alternative repression mark 
(Figure 4B) (Cao et al., 2014). 
The canonical PRC1 (cPRC1) complexes consists of the CBX transcription factors, which are 
capable of specific binding to H3K27me3. The catalytic subunit of the cPRC1 is an E3 
ubiquitin ligase imparting factor Ring finger protein 1 (RING1) or its homolog Ring finger 
protein 2 (RNF2), that can deposit H2AK119ub1 (Aranda et al., 2015). The RING1/RNF2 
subunits are always bound to either Polycomb group ring finger 2 (PCGF2) or Polycomb group 
ring finger 4 (PCGF4) which together with CBX factors constitute to the core of the cPRC1 
complex’s (Figure 4B). The cPRC1s are categorized based on the presence of PCGF2 and 
PCGF4 as cPRC1.2 and cPRC1.4 complexes respectively (Geng & Gao, 2020). 
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Another variant of the PRC1 complexes, the non-canonical PRC1s (ncPRC1s) (also called as 
the variant PRC1(vPRC1s)) were also identified in later studies, in which the canonical core 
subunit of the cPRC1s CBX is replaced by RYBP or its homolog YY1 associated factor 2 
(YAF2) (Gao et al., 2012). As the CBX subunits are replaced by RYBP and YAF2 which lack 
the chromobox domains in the ncPRC1s, these complexes are not capable to recognise and 
bind to H3K27me3. RYBP is able to recognise and bind to the H2AK119ub1 mark (Zhao et 
al., 2020) at the repressed genes and deposits further H2AK119ub1 through the RING proteins, 
aiding the compaction of the chromatin and enabling more stable gene repression of the 
targeted loci by the ncPRC1s (Blackledge et al., 2014; Martinez et al., 2020) (Figure 4C). The 
ncPRC1s are categorized based on the presence of either of the 6 PCGF factors to form the 
core of the complex along with RING1/RNF2 and the RYBP/YAF2.  
Early models of maintained epigenetic repression of genes are generally referred as the 
“hierarchical recruitment of the PRC complexes” (Dorafshan et al., 2017). The proposed idea 
involves the initial assembly and binding of the PRC2 complex at the promoters of repressed 
genes. EZH2 imparts the catalytic functions of PRC2 by depositing H3K27me3 which is 
recognised and bound by the chromobox domain of the CBX factors from the cPRC1. The 
RING proteins RING1/RNF2 deposits H2AK119ub1 which facilitates repression of the 
chromatin by histone compaction. The ncPRC1 comprising RYBP then recognises the histone 
ubiquitination and exerts H2AK119ub1 for further chromatin compaction and more stable 
repression. These controlled mechanisms maintain a gene repressed thoroughly during lineage 




Figure 4: Composition and activities of different PRC complexes. core-members and their 
main interacting partners are indicated 
Subunit compositions of the core of (A) PRC2, (B) cPRC1 and (C) ncPRC1 are represented in 
the schematic illustration. SUZ12, EZH2, EED and RBBP4/7 form the core of the PRC2 
complex. The PRC2 complex deposits H3K27me3 for gene repression. The cPRC1 complex 
contains CBXs, PCGFs, RING1/RNF2 and PHCs as the core complex members. cPRC1 can 
deposit H2AK119ub1 for chromatin compaction and gene repression. The core of the ncPRC1 
complex includes ubiquitination binding RYBP, PCGFs and RING1/RNF2. The RING1/RNF2 
in the cPRC1 and ncPRC1 can deposit H2AK119ub1 and are capable to cause chromatin 
compaction and gene repression. Abbreviations: PRC2: Polycomb repressive complex 2, 
cPRC1: canonical Polycomb repressive complex 1, ncPRC1/vPRC1: non canonical/variant 
Polycomb repressive complex 1. 
1.7 Role of RYBP in mouse embryogenesis  
In the last few years, the loss of function mutations of several PcG genes and the use of high-
throughput experiments like RNA-seq and ChIP-seq have revealed the major target genes of 
different PRCs in the regulation of developmental genes relating to different lineages. 
Rybp is essential for mammalian development as the Rybp knock out homozygous mice were 
embryonic lethal during the peri-implantation stages and a portion of the Rybp heterozygous 
















































studies have demonstrated the important role of RYBP in the development of organ systems 
such as the central nervous system (Pirity et al., 2005), hematopoietic system (Calés et al., 
2016), testis development (Tian et al., 2020) and the formation of the eye (Pirity et al., 2007).  
Due to the limitations poised by early embryonic lethality of the homozygous mice, in vitro 
based differentiation model systems were preferred to be utilized for analysing the role of 
RYBP during early lineage commitment (Ujhelly et al., 2015; Kovacs et al., 2016; Henry et 
al., 2020).  
1.8 The role of Rybp in cardiac development 
In my thesis work, I utilized wild type and Rybp null mutant ES cells. The mutant ES cells 
proliferate normally, maintain pluripotency and initiate differentiation towards multiple 
lineages (Ujhelly et al., 2015; Kovacs et al., 2016; Henry et al., 2020) making this cell line 
suitable for differentiation-based studies to elucidate the functions of RYBP.  
We have previously identified that mouse ES cells lacking Rybp could not form beating CMCs 
upon in vitro cardiac differentiation (Ujhelly et al., 2015). The expression of several key cardiac 
transcription factors including cardiac progenitor formation markers Isl1 and Tbx5 were 
deficient in the Rybp-/- CMCs in comparison to the wild type during the time course of in vitro 
cardiac differentiation. The deficient expression of Isl1 and Tbx5 are connected to the 
formation of CHD conditions in vivo, in mice (detailed in chapter 1.1). Moreover, Cardiac 
troponin T2 (Tnnt2), a major sarcomere component of wild type CMCs was amongst the most 
downregulated genes in the Rybp null mutant, suggesting that these gene expression changes 
were likely to contribute to the contractility defect of the Rybp mutant cell line (Ujhelly et al., 
2015). One of the most strikingly downregulated genes in the Rybp null mutant cells was 
Plagl1, a key cardiac transcription factor identified to affect chamber specification in the 
developing mouse heart (Yuasa et al., 2010). 
1.9 Overview of the regulatory activities of RYBP 
RYBP is a moonlighting protein, which exerts different functions based on its versatile 
interacting partners (Neira et al., 2009). As specified earlier, RYBP is a member of the 
ncPRC1s, which functions as a repressor of genes distinctive to multiple lineages during 
developmental process (Figure 5A) (Garcia et al., 1999). Although as part of the ncPRC1.3 and 
the ncPRC1.5 complex, RYBP can also exert activation functions (Figure 5B) (Gao et al., 
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2014). The interaction of Autism related Autism susceptibility candidate 2 (AUTS2) and 
Casein kinase 2 (CK2) with the ncPRC1.3 and ncPRC1.5 complex was key in exerting the 
activation functions of the complexes in central nervous system (Gao et al., 2014). Further, in 
ES cells, the ncPRC1.3 and ncPRC1.5 complexes were identified to interact with Testis 
expressed 10 (TEX10) and E1a binding protein p300 (P300) to activate gene expression (Zhao 
et al., 2017). 
ChIP-seq experiments displayed the binding of RYBP at various genomic loci independent to 
the binding of its PRC1 co-factor RNF2 indicating that polycomb independent regulatory 
activities of RYBP does also exist (Morey et al., 2015; Bajusz et al., 2018). Recent studies have 
revealed that the repressive activities of RYBP depends on the ability of RYBP to recognise 
and bind to H2AK119ub1- a repression mark and the initiation of further compaction upon 
binding (detailed in chapter 1.5) (Rose et al., 2016; Zhao et al., 2020; Barbour et al., 2020). No 
consensus DNA binding has been established for RYBP yet, but the protein is able to associate 
with DNA binding transcription factors such as Pluripotency factor POU domain, class 5 
transcription factor 1 (POU5F1, also called as OCT4), E2F transcription factors 2 and 3 (E2F2 
and E2F3) and YY1 transcription factor (YY1). The association of RYBP with these 
transcription factors generally lead to the activation of the targeted gene loci. For example, 
RYBP associated with OCT4 to activate lysine (K)-specific demethylase 2B (Kdm2b), a 
histone demethylase which can recruit PRCs to developmental genes in ES cells (Figure 5C) 
(Li et al., 2017; He et al., 2013). RYBP is also demonstrated to bridge the interaction between 
E2F and YY1 transcription factors to activate Cell division cycle 6 (Cdc6) (Figure 5D) 
(Schlisio et al., 2002).  
Since the emerging studies showed the connections between the expression of RYBP and 






Figure 5: Different regulatory activities of RYBP 
Schematic illustration representing: (A) the polycomb dependent repression function of RYBP 
(Bajusz et al., 2019), (B) the ncPRC1.3 and ncPRC1.5 complex in which RYBP is a member of 
can exert activation mechanism (Gao et al., 2014), (C) RYBP association with OCT4 activated 
pluripotency genes (Li et al., 2017) and (D) RYBP associates with YY1 and either E2F2 or 
E2F3 transcription factors to activate Cdc6 expression (Schlisio et al., 2002).  
1.10 Relativeness between the functions of RYBP and PLAGL1  
Genome wide transcriptomics of the wild type and Rybp null mutant ES cells and derived 
CMCs revealed altered expression of several cardiac genes crucial for the functional 
morphogenesis of a developing heart (Ujhelly et al., 2015). Plagl1 was one of the most down 
regulated genes in both the Rybp null mutant ES cells and derived CMCs. Intriguingly, the 
Plagl1 homozygous mice was also embryonic lethal as Rybp and the heterozygous mice 
resembled the neural tube defects of the Rybp heterozygous mice (Yuasa et al., 2010). Plagl1 
is also shown to be expressed in the cerebellum of the brain and showed exencephaly defects 
which were also seen in the Rybp heterozygous mice (Pirity et al., 2005; Yuasa et al., 2010). 
During organogenesis, RYBP and PLAGL1 are co-expressed in the developing organ systems 
such as the central nervous system, the heart and the eye (Table 2) (Valente & Auladell, 2001; 
Miró et al., 2009; Pirity et al., 2005; Garcia et al., 1999; Pirity et al., 2007). 
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PLAGL1 is also called as Zinc finger protein inducer of apoptosis and cell cycle arrest (ZAC1) 
due to its roles in apoptosis (Spengler et al., 1997) similar to RYBP (Stanton et al., 2007). Both 
RYBP (Tan et al., 2017; Voruganti et al., 2015; Zhu et al., 2017) and PLAGL1 (Abdollahi et 
al., 1999; Bilanges et al., 1999) have been identified to function as tumor suppressors as well. 
Both RYBP and PLAGL1 are previously identified to physically interact with tumor suppressor 
Transformation related protein 53 (TRP53, also called as P53). RYBP can modulate the 
stability of P53 by inhibiting ubiquitination of the protein (Chen et al., 2009). On the other 
hand, PLAGL1 can interact with p53 to activate the expression of Cyclin-dependent kinase 
inhibitor 1A (Cdkn1a, also called as p21) to regulate cell cycle exit (Liu et al., 2008; Benedetti 
et al., 2017). Taken together, these suggested a possible genetic or biochemical connection 














Table 2: Gene expression of Rybp and Plagl1 in mouse embryonic tissues 
The expression of Rybp and Plagl1 in in vivo mouse tissues based on previously analysed data 
from RNA-in situ hybridisation experiments are presented in the table. Rybp and Plagl1 are 
co-expressed in the same tissue types in the CNS, heart and the eye. + denotes presence of the 
respective factors, ++ denotes stronger expression, - denotes no expression and ± denotes 
weak expression of Rybp or Plagl1. Abbreviation: ND-no data. 
1.11 Plagl1, as a key cardiac transcription factor 
Mouse Plagl1 has been identified as a transcription factor with diverse functions, expressed at 
various developing tissues during embryonic developmental and adult stages (Table 2) 
(Valente & Auladell, 2001; Alam et al., 2005). Plagl1 expressed strongly in the forelimb, 
hindlimb, liver primordium, neural tube, neural retina, primordial heart, epithalamus, pituitary 
lobe, choroid plexus, cortical plate, marginal zone, hippocampus, atrium, ventricle in the 
developing embryo (Valente & Auladell, 2001; Valente et al., 2005; Alam et al., 2005) 









Forebrain ++ ND + ND Garcia et al, 1999  Valente et al, 2001
Midbrain + ND ++ ND  Pirity et al, 2005  Valente et al, 2001; Alam et al, 2005
Hindbrain ++ ND ++ ND Garcia et al, 1999  Valente et al, 2001; Alam et al, 2005
Cortical plate ++ ND + ND  Pirity et al, 2005  Valente et al, 2001; Alam et al, 2005
Marginal zone ++ ND + -  Pirity et al, 2005  Valente et al, 2001
Hippocampus ++ ND + ++ Pirity et al, 2005  Valente et al, 2001; Alam et al, 2005
Ventricular zone - ND ++ ±  Pirity et al, 2005;  Valente et al, 2001; Alam et al, 2005
Sub-ventricular zone + ND + ±  Pirity et al, 2005  Valente et al, 2001; Alam et al, 2005
Choroid plexus ND ND ++ +  Valente et al, 2001
Retina ++ ++ + +  Pirity et al, 2007 Alam et al, 2005
Lens ++ - + ±  Pirity et al, 2007 Alam et al, 2005
Cornea ++ ± ND ND  Pirity et al, 2007 Alam et al, 2005




Yuasa et al, 2010; Tsuda 






















Atrium and Ventricle ++ + ++ ++
Pirity et al, 2005; Garcia 
et al, 1999; Ujhelly et al, 
2015 
Pirity et al, 2005  Valente et al, 2001, Miró X et al,2009




+ ND + ±
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PLAGL1 is determined to be a cardiac transcription factor with chamber specific expression in 
the developing heart (Tsuda et al., 2004; Yuasa et al., 2010). Plagl1 heterozygous exhibited 
atrial and ventricular septal defects and improper chamber specification in the E15.5 hearts 
(Yuasa et al., 2010). Plagl1 is shown to be regulated by the cardiac transcription factors NKX2-
5 in mouse and by MEF2C in rat mesenchymal cells (Yuasa et al., 2010; Czubryt et al., 2010). 
These studies established PLAGL1 as a cardiac transcription factor, regulated by cardiac 
progenitor transcription factors during mammalian heart development. 
1.12 Relevance of Plagl1 towards diseases  
Plagl1 encodes for zinc finger type transcription factor with anti-proliferative activity and is a 
presumptive tumour suppressor gene on 10q24 which expression is frequently lost in various 
neoplasms. Alterations of Plagl1 expression were profoundly classified in various cancers such 
as breast, ovarian primary tumors and also in tumor derived cell lines, basal cell carcinoma and 
Extraskeletal myxoid chondrosarcoma (EMC) (Cvetkovic et al., 2004; Jacobs et al., 2013; 
Kowalczyk et al., 2015; Li et al., 2014; Ribarska et al., 2014). Allelic deletions of Plagl1 have 
been implicated in different cancers as well (Kowalczyk et al., 2015). Like most imprinted 
genes, a differentially methylated region (DMR), rich in CpG sequences, are influencing Plagl1 
transcription. An in vitro model for Plagl1 gene regulation demonstrated that methylation of 
the CpG islands induces heterochromatin modification that represses gene transcription 
(Varrault et al., 2001).  
Furthermore, the biallelic expression of Plagl1 from an alternate promoter is associated to 
transient neonatal diabetes mellitus (TNDM) (Hoffmann, 2015). The expression of both Plagl1 
and the non-coding RNA (ncRNA) in its locus, Hydatiform mole associated and imprinted 
(Hymai) were identified to be higher in TNDM conditions (Arima et al., 2001).  
These studies indicated the important role of Plagl1 not only in normal mammalian 










The aims of this thesis study were to understand the connections between epigenetic factor 
RYBP and cardiac transcription factor Plagl1 during in vitro cardiomyogenesis and to broaden 
our knowledge about the functions of RYBP during cardiac development. Our focus was 
directed towards unravelling the specific molecular mechanisms by which RYBP affected the 
regulation of key cardiac transcription factors such as Plagl1 and to understand the critical role 
of Plagl1 in the formation of contractile CMCs.  
 
The detailed aims of the thesis were: 
 
i. To examine the expression of Plagl1 and compare it with the expression of Rybp 
during in vitro cardiac differentiation. 
 
ii. To characterize and compare the protein localization of RYBP and PLAGL1. 
 
iii. To identify putative regulatory elements in the Plagl1 genomic locus. 
 
















3. MATERIALS AND METHODS 
3.1 Cell culture techniques 
3.1.1 Cell lines and culture conditions 
Mouse (129SV/Ola) R1 ES cells (Nagy et al., 1993) (mentioned as wild type or Rybp+/+) and 
D11 ES cells (mentioned as Rybp null mutant or Rybp-/-) (M K Pirity et al., 2005)(Figure 6) 
were thawed on mitomycin C (Mit C; Sigma, Cat.No M0503) inactivated mouse embryonic 
fibroblast (MEF) layer and cultured on 0.1% gelatin (Gelatin from bovine skin, Sigma, Cat.No 
G-9391) coated tissue culture plates as described in Magin et al (Magin et al., 1992). The cells 
were maintained in Dulbecco’s modified eagle’s medium (DMEM (1x) + Gluta MAXTM-1 
Dulbecco’s Modified Eagle Medium, Gibco, Cat.No 31966-021) containing 15% Fetal Bovine 
Serum (FBS) (APS, Cat.No S-001A-USDA grade), 0.1 mM non-essential amino acids (MEM 
Non-Essential Amino Acids (100x), Corning, Cat. No 34319012), 0.1 mM ß-mercaptoethanol 
(2-Mercaptoethanol, Gibco, Cat.No 31350-010), 1% sodium pyruvate (Sodium Pyruvate 
(100mM) (100x), Gibco, Cat. No 11360-039), 1% glutamine (L-Glutamine (200 mM) Gibco, 
Cat.No 25030-024), 50 U/ml penicillin/streptomycin (Penicillin/ Streptomycin (100x), Gibco, 
Cat.No 15140-122) and 100 U/ml Leukemia inhibitory factor (LIF, ESGRO, Chemicon/ 
Millipore, Billerica, MA, USA). The cells were passaged prior to reaching 70% confluence 
(approximately every second day). ES cells were cultured on gelatin coated dishes for at least 
three passages prior to differentiation to deplete potentially present MEF cells from the ES cell 
culture. Cells were cultured in humidified conditions containing 5% CO2 at 37°C. The cells 
were grown with fresh ES cell media supplemented every day. 
Human Embryonic Kidney (HEK) 293T cells was used for PLAGL1 protein assays. HEK293T 
cells were maintained in Dulbecco’s modified eagle’s medium (DMEM (1x) + Gluta MAXTM-
1 Dulbecco’s Modified Eagle Medium, Gibco, Cat.No 31966-021) containing 10% FBS (Gibco, 
Cat.No 10500-064), 0.1mM non-essential amino acids (MEM Non-Essential Amino Acids 
(100x), GIBCO, Cat.No 11140-035), 1% sodium pyruvate (Sodium Pyruvate (100 mM), 
Gibco, Cat.No 11360-039) and 50 U/ml penicillin/streptomycin (Penicillin/Streptomycin 
(100x), GIBCO, Cat.No 15140-122). The cells were passaged before the confluency reached 
90% (approximately every 2-3 days). Medium was changed every second day. Cells were 




Figure 6: ES cell lines used in this study  
Rybp genomic locus (Chr6: 100228565-100287358) contains 5 exons in the wild type (Rybp+/+) 
ES cells. In the Rybp null mutant (Rybp-/-) ES cells, the 3’ of exon 3, exon 4 and exon 5 are 
replaced by a donor cassette containing Enhanced Yellow Fluorescent Protein (EYFP) 
followed by a floxed neomycin-phosphotransferase (NEO) cassette (Pirity et al., 2005). 
3.1.2 In vitro cardiac differentiation of mouse embryonic stem cells 
Mouse ES cells were harvested as single cell suspension using 0.05% (wt/vol) trypsin (Trypsin-
EDTA (1x) 0,05% / 0,02% in D-PBS, GIBCO, Cat.No 15400-054) and then the cell number 
was calculated using a Burker chamber. The cell number was diluted to 50 cells/µl in 
suspension and 20 µl droplets of cell suspension were dispensed to lids of bacterial dishes 
where each droplet contained around 1000 cells, and then the cells were let to form EBs by the 
HD method as described in Keller et al. (Keller, 1995) (Figure 7). The EBs were harvested on 
the second day and plated into cell culture dishes (60 mm, Corning, Cat.No 430196) coated 
with gelatin containing ES medium (described in 3.1.1) without LIF. The medium was changed 
every second day and the cells were cultured to a maximum of 21 days. The cells were 
harvested for further analysis at different time points of cardiac differentiation: day 0, 2, 7, 10, 
14 and 21 (labelled as d0, d2, d7, d10, d14 and d21). Day 0 represents pluripotent stem cell 
stage, day 2 represents the EB stage, day 7 and day 10 represents early and late cardiac 
progenitor stages respectively and day 14 and day 21 represents the terminal stage of in vitro 
cardiac differentiation.  
Rybp+/+
Rybp-/-
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Figure 7: In vitro cardiac differentiation 
CMCs were differentiated in vitro from ES cells through EB formation by using the HD method. 
Cardiac colonies were grown for maximum 21 days, sampled for mRNA expression analysis 
(qRT-PCR) and fixed for ICC analysis at day (d) 0, 2, 7, 10, 14 and 21 (indicated in bold). 
Samples were derived earlier at d0, d8 and d14 for whole genome transcriptomics as described 
previously (Henry et al., 2020; Ujhelly et al., 2015). For the analysis of the initial time points 
of Plagl1 expression, samples were derived at an extended interim time points between day 0 
till day 7 (i.e., d2, 3, 4, 5, and 6) for qRT-PCR and ICC analysis. Abbreviations: ES cells: 
Embryonic stem cells, EBs: Embryoid bodies, HD: Hanging drops, CMCs: Cardiomyocytes, 
ICC: Immunocytochemistry, qRT-PCR: quantitative real-time polymerase chain reaction.  
3.1.3 Calcium Phosphate transient transfection method 
Calcium Phosphate method (Kingston et al., 2003) was used to transiently transfect HEK293T 
cells for reporter assays and protein overexpression for protein stability assays (methods 3.3.2) 
and co-immunoprecipitation (Co-IP, methods 3.3.3) analysis. HEK293T cells were seeded at a 
density of 1 x 106 cells per 6 cm tissue culture dishes and maintained as described above. 5 
hours before transfection the cells were fed with fresh medium. The transfection mix were 
prepared by diluting the required plasmids in 0.1 mM Tris-EDTA (Trizma base, Sigma, Cat.No 
T1503) buffer and 2.5 M Calcium chloride (CaCl2, Sigma, C-3881) and 2X HEPES buffered 
saline (HBS, Sigma, Cat.No H3375) dropwise by bubbling the solution using Pasteur pipette 
to provide oxygen for the mixture. The transfection mix was added to the cells dropwise and 
the cells were then maintained with the transfection mix in humidified conditions. 16 hours 
after the transfection, fresh media was provided to the cells and after 40 hours the cells were 
washed twice with 2ml of 1X PBS on ice and then harvested for whole cell protein lysate using 
cell lysis buffer (Cell culture lysis 5X reagent, Promega, Cat.No E153). 
d0 d2 d7 d10 d14 d21d8
ES cells
(Pluripotent) Embryoid bodies (EBs) Cardiac progenitor formation Terminal cardiac (CMCs)
d3 d4 d5 d6
Extended time points for Plagl1
expression analysis
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3.1.4 The luciferase reporter assay system 
HEK293T cells was transfected with Calcium Phosphate transient transfection method as 
mentioned above (3.1.4) (Figure 8). The transfected cells were harvested for their protein 
lysates 40 hours after transfection with 1X Passive lysis buffer (1X PLB) provided by the 
luciferase assay kit (Dual Luciferase Reporter Assay System, Promega, Cat.No E1910) (Figure 
8). Concentration of the whole cell lysate was determined by the Bradford’s method (5X Bio-
Rad Protein Assay Dye reagent concentrate, Cat.No 5000006) according to the manufacturer’s 
instructions. Protein concentrations were measured from OD600 taken in UV spectrophotometer 
(WPA Photometer UV110 Cambridge, UK, Cat.No RS232). The concentration of the lysates 
was then determined by Bradford’s method (Bradford, 1976) using Bovine Serum Albumin 
(BSA, VWR, Cat.No G22361V) as the standard. 20 µg of the protein lysates were measured 
from each transfection with 100 µl of Luciferase Assay Reagent II (LAR II, provided with the 
kit). Luciferase activity was recorded with Perkin Elmer TopCount NXT Luminometer in dark 
conditions. Each measurement was recorded in triplicates. 
 
Figure 8: Flow chart of the working model for luciferase reporter assay  
Schematic representation of the workflow for luciferase reporter assay. 1 x 106 HEK293T cells 
were seeded in 6 cm petri dishes and on d2 were transfected with the required plasmids by 
Calcium Phosphate method. 16 hours after transfection the cells were fed with fresh media and 
after 40 hours the cells were harvested for the protein cell lysates. The cells transfected with 
EGFP was checked to measure the transfection efficiency and the samples were prepared for 
luciferase measurement as described in 3.1.4. 
Day 1: Seeding 1 x 106 HEK293T cells/6cm
Day 2: CaPO4 transfections of plasmids
Day 3: Feeding




Detect the luciferase levels 
using luminometer
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3.1.5 Inhibition of PRC1 activity  
Inhibition of PRC1 activity was performed to analyse the PRC1 dependent and independent 
activities of RYBP in promoter assays. 16 hours after transfection of the required plasmids by 
Calcium Phosphate method (detailed in 3.1.4), HEK293T cells were fed with growth media 
supplemented with 50 µM of PRC1 inhibitor, PRT4165 (PRT4165, Sigma, Cat.No 
NSC600157) as previously reported by Ismail et al. and Gracheva et al. (Ismail et al., 2013; 
Gracheva et al., 2016). The cells were maintained with PRT4165 supplemented media for 
further 1 hour after treatment and the whole cell lysates were procured. The cell lysates were 
then prepared for luciferase reporter assay as described in 3.1.4. 
3.2 Molecular biology techniques  
3.2.1 Quantitative real-time PCR (qRT-PCR) 
Relative quantification of mRNA expression during in vitro cardiac differentiation was 
performed using quantitative real-time PCR (qRT-PCR). Total RNA was isolated from the 
harvested cells at the required time points of in vitro cardiac differentiation (described in 3.1.2) 
using GeneJET RNA Purification Kit (Thermo Scientific, Cat.No K0732) according to the 
manufacturer’s instruction. Reverse transcription PCR for the cDNA synthesis from the 
isolated RNA was performed using Applied Biosystems High-capacity cDNA Reverse 
Transcription Kit (Invitrogen Life Technologies, Cat.No 4368814) according to the 
manufacturer’s instructions. qRT-PCR analysis was performed with SYBR green master mix 
(SYBR® Select Master Mix for CFX, Applied Biosystems, Cat.No 4472942) using Bioer 
LineGene Real-time PCR system (Bioer, China).  
Relative mRNA expression changes were determined using the ∆∆Ct method. The threshold 
cycle (Ct) values for each gene were normalized to the expression level of Hprt (Hypoxanthine 
guanine phosphoribosyl transferase I) as internal control. The data is presented as fold 
expression changes normalized to wild type d0. The primers used in this study are listed in 




Table 3: Primers used in qRT-PCR reactions 
3.2.2 Chromatin Immunoprecipitation and qRT-PCR (ChIP-qRT-PCR) 
Chromatin immunoprecipitation (ChIP) was performed by using EpiXplore ChIP kit, 
(Clonetech, Cat.No 632011) according to manufacturer’s instructions. In brief nuclear 
extraction from ES cells and d7 cardiac differentiated cells from 10 cm plates was carried out 
by carefully lysing the cytoplasm and nuclei using the lysis buffers (provided in the kit) and 
subsequent shearing of the DNA was performed using an ultrasonicator (Ultrasonic 
homogenizer 3000, BioLogics) at 4x30 s cycles, 60 pulse and 20 kHz. The sheared DNA was 
loaded into 1 % Agarose gel electrophoresis (AGE) and the size of the sheared chromatin was 
seen between 200 bp to 800 bp (ideal for IP and qRT-PCR). The sheared DNA was then 
incubated with prewashed magnetic beads (Mag Capture beads, Clonetech, Cat.No 632577) 
under gentle rocking for 4 hours at 4°C. The wash steps were carried out according to the 
manufacturer’s instructions with the help of a magnetic stand. The eluted immunoprecipitated 
chromatin was then treated with RNase A and Proteinase K (provided in the kit).  
The immunoprecipitated chromatin was then used for qRT-PCR using SYBR green as 
described in 3.2.1. 
 
 
Gene Name Forward Primer sequence Reverse primer sequence
Hprt 5'- AGTCCCAGCGTCGTGATTAG-3' 5'-GCAAGTCTTTCAGTCCTGTCC-3'
Rybp 5'-TTAGGAACAGCGCCGAAG-3' 5'-GCCACCAGCTGAGAATTGAT-3'
Plagl1 ex 1/2 5'-AGCAAGGCTTCTCACAGGC-3' 5'-GTGAGGTACTTCCTTCAGCATCTTG-3'
Plagl1 ex 4/5 5'-GATTGCTTCAGCGTGCCATCG-3' 5'-ACTCCTCTGACTCCTATGCAAA-3'





Figure 9: Sheared chromatin of d0 wild type ES cells used for ChIP-qPCR 
Wild type ES cells were harvested from 10 cm petri dishes and the isolated nuclear fractions 
with the chromatin was sheared by sonication. The sonicated sheared chromatin was loaded 
in 2% AGE with 100 bp ladder (GelPilot 100 bp ladder, Qiagen, Cat.No 239045) in the left. 
The size of the ladder bands is labelled accordingly. The isolated chromatin was sheared at an 
average size of 200-800 bp in length which is ideal to use in qRT-PCR. Abbreviations: kb: 
kilobase, bp: base pair. 
3.2.3 Molecular cloning, transformation and confirmation 
All enzymes required for molecular cloning of promoter and cDNA constructs of interest were 
performed using NEB enzymes. Amplification of the promoter regions was done using BAC 
clone (RP23-259L24 BAC clone for Plagl1 promoters) or using wild type genomic DNA 
(gDNA) isolated from ES cells (for Tnnt2 promoter) as the template. One Taq Hot Start DNA 
Polymerase kit (NEB, Cat.No M0481S) was used for the amplification of DNA following the 
manufacturer’s instructions. 
The Plagl1 P1 promoter (4612 bp) was PCR amplified using 5’ and 3’ HindIII site containing 
primers from RP23-259L24 BAC (RPCI23-259L24, BACPAC resource, RPCI) construct 
(Table 4). The amplified DNA was gel eluted using QIAquick Gel Extraction kit (Qiagen, 
Cat.No 28706) according to the manufacturer’s instructions and cloned into the HindIII site of 
the MCS (multiple cloning site) in the pGL4.20 vector (Figure 10A) (pGL4.20 (luc2/Puro) 

















The Plagl1 P2 promoter (1821 bp) was also amplified and cloned using 5’ and 3’ HindIII site 
containing primers (Table 4). The P2 promoter was cloned into pGL4.20 vector (Figure 10B) 
as mentioned above. 
The Plagl1 P3 promoter containing pGL3-mZac1pr (henceforth called as the Plagl1 P3 
promoter) construct (Figure 10C) was a kind gift from Dr. Michael Czubryt, Institute of 
Cardiovascular Sciences, University of Manitoba, Canada. 
 
 
Figure 10: Schematic representation of the generated Plagl1 promoters containing 
luciferase reporter constructs 
The (A) Plagl1 P1 and (B) P2 promoter regions were cloned at the HindIII sites immediately 
upstream to the luciferase coding region in pGL4.20 Luc2 vector. Plagl1 P3 promoter (C) 
incorporating luciferase reporter construct was a kind gift from Dr. Michael Czubryt. The 
constructs were labelled as pGL4.20 Plagl1 P1, pGL4.20 Plagl1 P2 and pGL3 Plagl1 P3 
according to the encompassing promoter region. The Plagl1 promoter regions are represented 
in green colour along with indicating cloning restriction sites, regulatory elements such as 






The subcloning of the P3 promoter was performed as follows. Clone a (1-2.8 kb) and f (2.8- 
5.4 kb) were produced by cleaving the P3 with BglII (Figure 10C). Clone a (1-2.8 kb) was self-
ligated after digestion with BglII and the 2.8-5.4 kb band was eluted and re-cloned into pGL3 
empty vector at the BglII site. Clones b (1-1.3 kb) and d (1.3- 2.8 kb) were generated by HindIII 
digestion of clone a. Clone c (1-1.6 kb) was generated by digesting clone a with PstI and self-
ligating the 6.5 kb band. Clone e (1.6-3.7 kb) construct was generated by digesting the Plagl1 
P3 promoter by PstI (Figure 10C). The 2.1 kb band after digestion with PstI was gel eluted and 
re-cloned into the same sites in pGL3 empty vector. Clone g (2.8-3.7 kb) and h (3.7-5.4 kb) 
were generated by digesting clone f with PstI and performing self-ligation and insert ligation 
of fragments as mentioned earlier. 
The Tnnt2 promoter (2688 kb) was PCR amplified using wild type gDNA from ES cells as 
template. The PCR amplicon was gel eluted and cloned into KpnI sites (Table 4) and cloned 
into pGL4.20 vector (Figure 11) as described above. 
 
Figure 11: Schematic representation of the generated Tnnt2 promoter containing luciferase 
reporter construct 
The Tnnt2 promoter was cloned at the KpnI sites immediately upstream to the luciferase coding 
region in pGL4.20 Luc2 vector. 
Tnnt2 promoter is represented in green colour along with indicating cloning restriction sites. 
cDNA overexpression constructs for Hymai (Figure 12A) and Plagl1it ncRNA (Figure 12B) 
were generated by PCR amplifying the ncRNAs from d14 cardiac differentiated wild type cells. 





Figure 12: Schematic representation of the Hymai and Plagl1it cDNA overexpression 
constructs 
Both (A) Hymai and (B) Plagl1it ncRNA were cloned at the XhoI sites in the pcDNA3.1- vector. 
The cloned cDNA region is represented in orange colour along with indicating vector elements. 
 
cDNA overexpression constructs were generated by PCR amplifying Nkx2-5 and Mef2c from 
cDNA pool generated from whole cell RNA isolated from d10 cardiac differentiated wild type 
cells. The PCR amplicons were gel eluted and cloned into the BamHI site in pRK7 FLAG 
vector in frame with the N-terminal FLAG tag. Both FLAG-NKX2-5 (Figure 13A) and FLAG-
MEF2C (Figure 13B) constructs produced N-terminally FLAG tagged proteins. 
Further confirmation of the cloned constructs was performed by orientation check of the ligated 








Figure 13: Schematic representation of the Nkx2-5 and Mef2c cDNA overexpression 
construct 
Both (A) Nkx2-5 and (B) Mef2c cDNA were cloned at the BamHI sites in frame with a N-
terminal FLAG tag. The cloned cDNA region is represented in maroon colour along with 
indicating vector elements. 
 
 
Table 4: Table of the primers used to clone the Plagl1 P1, P2, Tnnt2 promoters and cDNA 
overexpression constructs in this study (3.2.3). 
3.2.4 Site directed mutagenesis 
Site directed mutagenesis was performed using Q5 site directed mutagenesis kit (NEB, Cat.No 
E0554S) following the manufacturer’s instructions. Primers were designed to mutate 
consensus sites for Nkx2-5 and Mef2c at the P3 promoter by using NEBase Changer tool 
(https://nebasechanger.neb.com) provided by NEB (Table 5). The primers were designed to 
mutate the consensus of 3 Nkx2-5 and one Mef2c sites by introducing BamHI and HindIII sites 
respectively at the consensus to assist with screening positive mutants harbouring the right 
mutation. The PCR reaction was set according to the corresponding primer annealing 
temperature suggested by NEBase Changer tool. The KLD (kinase, ligase and DpnI digestion) 
enzyme (provided in the kit) was used to digest template DNA and ligation for rapid generation 
of mutant constructs carrying mutation for Nkx2-5 and Mef2c consensus. The transformed 
A B
Gene Name Forward Primer sequence Reverse primer sequence
Plagl1 P1 5'-GCTGAAGCTTATTAACCGCCTCATTCTCA-3' 5'-TACTAAGCTTTGGGTCTGATGGTTCCATAGA-3'
Plagl1 P2 5'-TGTAAGCTTCACTTTTCCTTTTGCAAGGCAT-3' 5'-TGTCAAGCTTAAGTGTGCAGAGGGAACTT-3'
Tnnt2 promoter 5'-TGATGGTACCGGAATCTAACAGTGTCTGGA-3' 5'-TATTGGTACCCCTCCCACAAGCTTACAATCA-3'
Hymai cDNA 5'-TATTCTCGAGCCCACGGCATCTGCGATTTG-3' 5'-ACGCTCGAGAGCATGTGAGGCAAATGACAAAC-3'
Plagl1it cDNA 5'-TATTCTCGAGCCTTGCTGCACGGACAGACT-3' 5'-GAGCTCGAGAGCAGCAACTGGGTGACATGC-3'
Nkx2-5 cDNA 5'-TAATTAGGATCCATGTTCCCCAGCCCTGC-3' 5'-TATTAGGATCCCTACCAGGCTCGGATGCC -3'
Mef2c cDNA 5'-AGCAGGATCCATGGGGAGAAA AAAGATTCAGA-3' 5'-TAATGGATCCTCATGTTGCCCATCCTTCAGAG-3'
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colonies were then screened and confirmed by BamHI and HindIII digestions for Nkx2-5 and 
Mef2c consensus sites respectively. Seven different mutants were generated harbouring single 
and multiple mutants of Nkx2-5 and Mef2c consensus (Figure 14). Further confirmation was 
performed by sequencing the plasmids (Deltagene, Szeged, Hungary) and checked for carrying 
the mutation with no off-target mutations in the constructs. 
 
 
Table 5: Table of the primers used to mutate Nkx2-5 and Mef2c sites at the P3 promoter in 




Figure 14: Schematic illustration of the position of Nkx2-5 and Mef2c sites and the 
generated mutants of the P3 promoter. 
The P3 promoter containing 3 Nkx2-5 (red colour) and 1 Mef2c (green colour) binding sites 
were mutated by the site directed mutagenesis method. The single mutants (1-4) and multiple 
mutants of the Nkx2-5 and Mef2c sites (5-7) were generated and labelled accordingly to the 




Name Forward Primer sequence Reverse primer sequence
Nkx2-5 (1) 5'-CTTGAATATCCATCTTGGAAGACCAAAATG-3' 5'-CTTTTGGGTCTTTGGGGGTGG
Nkx2-5 (2) 5'-TCCCATTTCCAAGCTTGTGGGCCTCAC-3' 5'-TTTCCATTTTGGTCTTCCAAG

























3.3 Biochemical assays 
3.3.1 Western blot analysis 
Analysis of proteins during in vitro cardiac differentiation was carried out by the Western blot 
technique. Whole cell lysates were isolated from differentiated samples by using 1x Passive 
lysis buffer (5x Passive lysis buffer, Promega, Cat.No E1941). Concentration of the whole cell 
lysate was determined by the Bradford’s method (detailed in 3.1.4). The protein samples were 
stored in 6X Laemmli dye (Laemmli, 1970) and 20 µg of the quantified total protein was then 
loaded in 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) 
using Bio-Rad Mini-Protean® 3 cell, Cat.No 67S/11919. The protein was then transferred to 
Polyvinylidene fluoride (PVDF transfer membrane, Immobilon®-P, Millipore, Cat.No 
IPVH00010) membrane and was hybridised with RYBP antibody, (anti-DEDAF, Merck 
Millipore, Cat.No AB3637, 1:1000) and PLAGL1 Antibody (anti-Zac1 C-7, Santa Cruz, 
Cat.No sc-166944, 1:1000). Bio-Rad Goat-anti-mouse IgG-HRP conjugate, (Cat.No 172-101, 
1:2000) and Merck Millipore Goat-anti-Rabbit IgG-HRP conjugate, (Cat.No AP132P, 1:2000) 
were used as the secondary antibodies. The membranes were washed with TBST buffer for 5 
times with 5 minutes of gentle shaking and then hybridised with Immobilon™ Western, 
Chemiluminescent HRP Substrate, Millipore, Cat.No WBKLS0500. Alliance Q9 system 
(UVITECH) was used to capture the chemiluminescent signals. 
3.3.2 Protein stability assays 
The wild type d14 differentiated cardiomyocytes were treated with 75 µg/ml concentration of 
Cyclohexamide, (CHX, Sigma, Cat.No C7698) and 10 µM MG132 (MG132, Cayman 
Chemicals, Cat.No 133407-82-6) for up to 6hours and the cells were then lysed in a time 
dependant manner between 1 hour and 6 hours of the treatment by using 1X Passive lysis buffer 
(5X Passive lysis buffer, Promega, Cat.No E1941) respectively. 
3.3.3 Co-Immunoprecipitation (Co-IP) 
HEK293T cells were transiently transfected with 5 µg of pcDNA3.1-RING1A FLAG, pRK7- 
FLAG NKX2-5, pRK7-FLAG MEF2C and pRK7-FLAG PLAGL1 (a kind gift from Dr. 
Dietmar Spengler, Max Plank Institute of Psychiatry, Germany) in combination with 5 µg of 
pcDNA3.1 RYBP cDNA containing expression vectors. Transient transfection and protein 
lysis were performed as mentioned above (detailed in 3.1.3). The whole cell lysates were 
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incubated in ice for 15 minutes and were spun at 15,000 x g for 10 minutes at 4°C. The 
supernatant was separated and pre-cleaned with 30 µl of Protein A-Agarose beads (Roche, 
Ref.No 11134515001) at 4°C under gentle rocking for 20 minutes. The precleared supernatant 
with agarose beads were spun at 500 x g for 2 minutes at 4°C. 80 µl of the supernatant was 
collected and mixed with 6X Laemmli dye, boiled for 10 minutes at 100°C to use as input 
lysates for Western blot analysis. The remainder of the supernatant was incubated overnight at 
4°C under gentle rocking with 30 µl of RYBP antibody (anti-DEDAF, Millipore, Cat.No 
AB3637) bound agarose beads (5 µl of RYBP antibody (1 µg/ml) was bound to 100 µl of 
agarose beads for 4 hours at 4°C under gentle rocking). To wash the immunoprecipitated 
proteins, the protein bound FLAG-tagged beads were centrifuged for at 500 x g for 2 minutes 
at 4°C and washed with 1X PBS for 5 times. The immunoprecipitated proteins bound to the 
RYBP-tagged beads were then mixed with 30 µl of 6X Laemmli dye, boiled for 10 minutes at 
100°C and stored in -20°C until further use. 20 µl of the input lysates and 20 µl of the 
immunoprecipitated proteins were loaded in 10 % SDS-PAGE and Western blot analysis 
(detailed in 3.3.2) was carried out. The Western transferred membrane was immunoblotted 
with anti-FLAG antibody (Monoclonal anti-FLAG M2 Peroxidase (HRP), Sigma, Cat.No 
A8592) at 4°C under gentle shaking overnight. The membranes were processed as mentioned 
in methods 3.3.2. 
3.3.4 Immunocytochemistry (ICC) analysis 
Immunofluorescence staining of in vitro cardiac cell cultures was achieved by culturing the 
cells over glass coverslips in 24 well plates (24 well Cell Culture Cluster Costar, Cat.No 3524) 
as described before (detailed in 3.1.2) and fixed with 4% Paraformaldehyde (PFA, Sigma, 
Cat.No 158127) for 20 minutes at room temperature (RT). Cells were permeabilized by 0.2% 
Triton X-100 (Triton® X-100, Sigma, Cat.No T8787) in Phosphate Bovine Saline (Dulbecco’s 
PBS (1x), Gibco, Cat.No 14190-144) for 20 minutes in gentle shaking at RT. 5% BSA in PBS 
was used to block the cells for 1 hour at RT. The cells were incubated with RYBP antibody 
(Anti-DEDAF antibody, Merck Millipore, Cat.No AB3637, 1:1000 dilution) and PLAGL1 
antibody (anti-Zac1 C-7, Santa Cruz, Cat.No sc-166944, 1:1000 dilution) in 5% BSA overnight 
at 4°C under gentle shaking. The cells were washed for 5 times with PBS and incubated with 
fluorescent labelled secondary antibody (Alexa Fluor 488 Goat-Anti-Rabbit, Invitrogen, 
Cat.No A-21206; Alexa Fluor 647 Donkey-Anti-Mouse, Invitrogen, Cat.No A-31571) at 
1:2000 dilution in BSA for 1 hour at 4°C. The cells were then washed 3 times with PBS. The 
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cells were then incubated for 20 minutes with DAPI (Vector Laboratories, Cat.No H-1200) 
diluted at 1:2500 in PBS. The cells were then washed 3 times with PBS and mounted in 
Fluoromount-G™, (eBioscience, Cat.No 00-4958-02). The images were taken in Olympus 
LSM confocal microscopy (Olympus Corporation, Japan). 
3.4 Bioinformatic analysis 
3.4.1 Transcriptome analysis  
Microarray analysis of the genome wide transcriptomics (Ujhelly et al., 2015) was carried out 
by mapping the sequenced reads from RNA-seq experiment by TopHat1 and the log2 fold 
change (FC) counts were calculated by read counts after normalization using DESeq1 package 
in R programming and deposited in GEO (Gene expression omnibus- 
https://www.ncbi.nlm.nih.gov/geo/) accession ID GSM4575880 (Henry et al., 2020). 
The sorting of the genes based on their corresponding log2 FC values was performed in 
Microsoft Excel using the VLookup and sorting functions. Hierarchical clustering of the values 
(log2 FC ≥ 2) for upregulation and (2 ≤ log2 FC) for downregulation of genes between wild 
type and Rybp null mutant ES cells and differentiated CMCs was performed by the k-means 
method using the XLSTAT extension tool in Microsoft Excel. Representative heatmaps were 
generated by transferring the clustered gene sets into Prism GraphPad 8 software.  
3.4.2 Analysis of the reported ESTs of the Plagl1 splice variants  
Complete CDS (coding sequence) of Plagl1 mRNA and deposited transcript variants were 
downloaded in FASTA format from NCBI-Nucleotide database. Each variant sequence was 
BLASTed with the Plagl1 genomic locus from Ensembl 
(https://www.ensembl.org/index.html) ID: ENSMUSG00000019817 as the reference file with 
indicating exon positions. The exons transcribed in each splice variant was identified and the 
splice variant sequences were aligned using BioEdit software. The corresponding position of 
the promoter region from which the splice variants were transcribed were presumed based on 
the coding exons and the relative position of the promoter regions.  
3.4.3 Analysis of functional domains and degron sites in PLAGL1 
The analysis for the functional domains in the PLAGL1 protein was determined by uploading 
the PLAGL1 amino acid (aa) sequence (NCBI ID: NP_033564.2) in the PROSITE ExPasy 
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Motif search tool (https://prosite.expasy.org) maintained by the Swiss Institute of 
Bioinformatics (SIB). Serine-threonine phosphorylation analysis was done by using kinase 
specific phosphorylation site prediction using GPS 5.0 online tool 
(http://gps.biocuckoo.cn/online.php) (Wang et al., 2020). Serine-threonine and tyrosine kinases 
sites in the PLAGL1 protein was predicted by setting high threshold cut-off. 
3.4.4 Analysis of the Plagl1 promoter for CpG islands and TATA box  
The CpG islands in the Plagl1 P1, P2 and P3 promoters were analysed by uploading the 
FASTA sequence in the DBCAT online tool (http://dbcat.cgm.ntu.edu.tw). DBCAT uses 
methylation microarray data to analytically identify the CpG islands in the query sequence. 
TATA box prediction was done by uploading the FASTA sequence of Plagl1 P1, P2 and P3 
promoters into YAPP Eukaryotic core promoter prediction webtool 
(http://www.bioinformatics.org/yapp/cgi-bin/yapp.cgi).  
3.4.5 Transcription factor binding analysis in Plagl1 promoters 
Transcription factors binding (TFB) analysis was performed using TRANSFAC webtool 
(https://genexplain.com/transfac/). TRANSFAC is a widely used TFB analysis tool which 
identifies TFB sites based on the experimentally proven consensus of several transcription 
factors and ChIP binding (Wingender et al., 1996; Wingender, 2008; Kaplun et al., 2016) . The 
amplified and cloned Plagl1 promoters P1, P2 and P3 promoter sequences were analysed for 
TFB sites by choosing either muscle specific, cell cycle specific or for all eukaryotic 
transcription factors. 
3.4.6 Motif search in gene promoter regions  
Promoter regions of sarcomeric genes- Actc1, Tnnt2, Tnni3, Tpm1, Tpm4, Myh7, Myom1 and 
Ttn were download from ENSEMBL (https://www.ensembl.org/index.html). ENSEMBL 
database identifies promoter regions in the chromatin based on metagenomic index containing  
pre-selected set of ChIP-Seq assays for CTCF, H3K4me1, H3K4me2, H3K4me3, H3K9ac, 
H3K27ac, H3K27me3, H3K36me3, H4K20me1 (Zerbino et al., 2015). The downloaded 
promoter regions in FASTA format were uploaded into JASPAR (http://jaspar.genereg.net/) 
database for motif search (Sandelin et al., 2004). The analysis was done by choosing Mus 
musculus PLAGL1, NKX2-5, MEF2C and TBX5. Predicted consensus sites and binding scores 
were used to generate Manhattan plot. Binding scores of over 10 was considered significant. 
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3.4.7 Metadata analysis in ES cells and CMCs 
Metadata analysis for existing ChIP-seq analysis was performed by downloading pre-existing 
ChIP-seq data from GEO database (https://www.ncbi.nlm.nih.gov/geo/) under the following 
IDs. In ES cells, RYBP ChIP- GSM4052120, RNF2 ChIP- GSM4052131 and input ChIP- 
GSM4052104 (Zepeda-Martinez et al., 2020), In differentiated CMCs, RYBP ChIP- 
GSM1657391, RNF2 ChIP- GSM1657390 and input ChIP- GSM1657392 (Morey et al., 2015).  
The downloaded BigWig files were uploaded into IGV (Integrative Genomics Viewer) 
choosing specific annotations i.e., mm9 or mm10 according to the original analysis and the 
binding peaks were visualized by setting the data range of the peaks using the input file as the 
reference. 
3.8 Statistical analysis 
All experiments were repeated three times. Experiments were evaluated by using two-way 
ANOVA for significance in qRT-PCR data and one-way ANOVA for significance in luciferase 
reporter assays using GraphPad Prism version 7. All data mentioned in this thesis are expressed 
as mean ± standard deviation (SD). Values of p ≤ 0.05 were accepted as significant (*p < 0.05; 



















4.1 Hierarchical gene cluster analysis of the whole genome transcriptome 
In order to get a global view of the transcriptional changes in the Rybp null mutant cells during 
cardiac differentiation, a detailed comparison of the mRNA transcriptomes across wild type 
and Rybp null mutant ES cells (d0) and derived CMCs (d8, d14) was previously performed 
(Ujhelly et al., 2015; Henry et al., 2020); GEO acc. GSE151349). In brief, wild type and Rybp 
null mutant ES cells were let to form EBs by the hanging drop method. On the second day the 
EBs were collected, plated on cell culture plates and cultured up to 14 days. The samples were 
collected from the designated time points of cardiac differentiation (methods 3.1.2) where d0 
represented the pluripotent stem cells stage, d8 the progenitor stage and d14 the terminal 
cardiac stage (Figure 7). In this analysis genes expression changes revealed that the levels of 
several key cardiac transcription factors part of signalling pathways and genes that code for 
proteins indispensable for contractility were downregulated (Ujhelly et al., 2015). In the frame 
of the current study, further analyses of the whole genome transcriptome data with functional 
annotations studies were carried out to identify the mechanisms that possibly led to the 
contractility defect of the Rybp null mutant CMCs. 
4.1.1 Calcium homeostasis, the JAK-STAT pathway and cell adhesion are 
amongst the most affected mechanisms in the Rybp-/- ES cells and derived CMCs 
Hierarchical clustering of the values (2 ≤ log2 fold change ≥ 2) between wild type and Rybp 
null mutant ES cells and differentiated CMCs was performed by the k-means method using 
XLSTAT tool revealed 8 distinct gene clusters (detailed in methods 3.4.1) (Figure 15A).  
From the analysis, clusters of genes with discrete fold change patterns during the analysed time 
points (methods 3.1.2) were procured (Figure 15A). Cluster 1 contained genes that were 
profoundly upregulated (log2 fold change ≥ 4) in ES (d0) at both examined stages of in vitro 
cardiac differentiation (i.e., d8 and d14) in the Rybp null mutant cells in comparison to the wild 
type (Figure 15B and C). These include Hyperpolarization-activated cyclic nucleotide-gated 
potassium and sodium channel 2 (Hcn2) and Hyperpolarization-activated cyclic nucleotide-
gated potassium and sodium channel 3 (Hcn3) (Figure 15B). High expression of Hcn2 and 
Hcn3 are associated to cause sinoatrial node dysfunction ultimately leading to heart failure 
(Yanni et al., 2011).  
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Other cardiac ion channel genes such as Potassium voltage-gated channel Isk-related subfamily 
member 1 (Kcne1), Potassium voltage-gated channel Isk-related subfamily member 2 (Kcne2), 
Calcium channel voltage-dependant gamma subunit 5 (Cacng5), Calcium-sensing receptor 
(Casr), Transient receptor potential cation channel subfamily V member 4 (Trpv4) and gap 
junction genes such as Gap junction protein beta 2 (Gjb2) were identified to be part of cluster 
1 (Figure 15B and C). These genes play essential roles in the maintenance of ion homeostasis 
in the developing CMCs.  
In cluster 2 we identified several genes with significantly upregulated expression level in the 
Rybp null mutant ES cells (log2 fold change ≥ 4) and decreased expression level at d8 and d14 
(log2 fold change ≤ 2) (Figure 15D and E). Genes that contribute to vascular smooth muscle 
contraction such as Angiotensin II receptor type 1 (Agtr1), Endothelin receptor type A (Ednra), 
Arginine vasopressin receptor 1a (Avpr1a), Myosin light chain kinase 3 (Mylk3 also called as 
Mlck) and Myosin light chain 2 (Myl2) that function in vasoconstriction and Adenosine A2a 
receptor (Adora2) that plays role in vasodilation were all part of the same cluster. Genes 
essential in maintaining calcium homeostasis in the developing CMCs such as Potassium 
inwardly-rectifying channel subfamily J member 5 (Kcnj5), Calcium voltage-gated channel T 
type alpha 1G subunit (Cacna1g), Calcitonin receptor (Calcr) and Sodium channel voltage-
gated type I alpha (Scn1a) were also identified in the same cluster showing that key cardiac 
genes were upregulated from the ES cell stage and these gene expression changes together 
could potentially lead to the loss of ion equilibrium which is required for the normal formation 
of CMCs (Figure 15D).  
Cluster 3 contained genes that were extensively downregulated at d8 and upregulated by d14 
in the Rybp null mutant cells (Figure 15F and G). By Gene Ontology (GO) analysis we 
identified 16 genes that acts on the JAK-STAT (Janus Kinase-Signal transducer and activator 
of transcription proteins) signalling pathway (GO:0046425) that contributes to the normal 
proliferation and apoptosis of the differentiating cells.  
In cluster 4, 5, 6 and 7 we did not identify genes that significantly related to any function 
connected to cardiac development. In cluster 8, cell adhesion markers such as Cadherin protein 
6, 7 and 17 (Cdh6, Cdh7 and Cdh17, respectively) and Vascular cell adhesion molecule 1 
(Vcam1) were identified to be downregulated in the Rybp null mutant ES cells (Figure 15H and 
I). Cell adhesion is a key feature which is required for the proper proliferation and 





Figure 15: Hierarchical gene clustering of transcriptome data from wild type and Rybp null 
mutant cells during in vitro cardiac differentiation. 
(A) Heat map from hierarchical clustering of RYBP regulated gene expression changes with 
significant upregulated (log2 fold change ≥2; green colour) and downregulated (log2 fold 
change ≤2; red colour) genes in the Rybp null mutant cells. The cluster numbers are listed on 
the right side of the heat map. (B and C) Cluster 1 heat map and tendency graph highlight the 
upregulated gene set at all three time points i.e., d0, d8 and d14. (D and E) Cluster 2 heat map 
and tendency graph highlight the genes upregulated in d0 only and downregulated in d8 and 
d14. (F and G) Cluster 3 heat map and tendency graph highlight the genes downregulated in 
d8 and upregulated in d14. (H and I) Cluster 8 heat map and tendency graph highlight the 
genes highly downregulated in d0. The tendency graphs are represented as an average of the 
overall log2 fold change for each time point pertaining to each cluster respectively. 
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4.1.2 Key cardiac transcription factors and sarcomeric components are 
downregulated in the Rybp null mutant CMCs 
To gain more insights about the expression of key cardiac genes which are vital for the 
formation of beating CMCs, we further dissected the transcriptome. Our analysis revealed that 
genes required for cardiac progenitor formation and sarcomere organization were remarkably 
downregulated at d8 and d14 in the mutant cells (Figure 16A). Cardiac progenitor markers Shh 
(d8 Log2 FC: -5.40, d14 Log2 FC: -2.42), Isl1(d8 Log2 FC: -1.14, d14 Log2 FC: -2.82), Nkx2-
5 (d8 Log2 FC: -9.14, d14 Log2 FC: -8.84) and Mef2c (d8 Log2 FC: -1.27, d14 Log2 FC: -1.02) 
displayed severe downregulation at d8 and d14 in Rybp-/- CMCs (Figure 16A). Cardiac 
transcription factors with known roles in first and second heart field specification such Hand2 
(d8 Log2 FC: -0.61, d14 Log2 FC: -0.08), Gata4 (d8 Log2 FC: -0.55, d14 Log2 FC: -0.22), Tbx5 
(d8 Log2 FC: -0.58, d14 Log2 FC: -0.98) and Tbx20 (d8 Log2 FC: -0.34, d14 Log2 FC: -0.13) 
also displayed faint downregulation at d8 and d14 in Rybp-/- CMCs. 
Sarcomeric genes such as Myomesin 1 (Myom1), Titin (Ttn), Actin alpha cardiac muscle 1 
(Actc1), Myosin heavy peptide 6 cardiac muscle alpha and Myosin heavy peptide 7 cardiac 
muscle beta (Myh6 and Myh7, respectively) were highly downregulated in the mutant cells 
(Figure 16B). This analysis shed light on the impairment of sarcomere formation, which can 
immensely contribute towards the non-contractility phenotype of the Rybp null mutant cells as 
well. 
 
Figure 16: Genes required for cardiac progenitor formation and sarcomere organisation are 
downregulated in the Rybp null mutant CMCs 
Log2 Fold change values from the transcriptome were used to generate bar graphs. (A) Bar 
graph representing the downregulation of genes functioning in cardiac progenitor formation 
in d8 and d14 differentiated Rybp null mutant CMCs. (B) Bar graph representing the 
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downregulation of sarcomeric genes in d8 and d14 differentiated Rybp null mutant CMCs. 
Abbreviations: d:day. 
4.2 Plagl1 is the most strikingly downregulated gene in the Rybp-/- ES cells and CMCs 
In the whole genome transcriptome analysis, Plagl1 a cardiac transcription factor with 
transactivation functions during mammalian embryonic development (Yuasa et al., 2010) was 
one of the most strikingly down regulated gene in the Rybp null mutant ES cells as well as 
derived CMCs (d0 Log2 FC: -3.79, d8 Log2 FC: -6.26, d14 Log2 FC: -6.53). In order to further 
characterize the expression of Plagl1 during an extended time course of in vitro cardiac 
differentiation (methods 3.1.2), we performed gene expression analysis by qRT-PCR. In brief, 
whole cell RNA was extracted from d0, d2, d7, d10, d14 and d21 time points of in vitro cardiac 
differentiation, reverse transcribed and qRT-PCR analysis was performed (details in methods 
3.2.1) (Primer list in Table 3). Gene expression changes were analysed using wild type and 
Rybp null mutant cells from the designated time points of in vitro cardiac differentiation. Our 
results showed that in the wild type cells (Rybp+/+), Plagl1 mRNA was first detectable from d7 
(cardiac progenitor formation stage) and its expression peaked by d14 and d21 (CMC stage) 
(Figure 17). Plagl1 was not expressed at any analysed time points of in vitro cardiac 
differentiation in the Rybp null mutant cultures (Figure 17). 
 
Figure 17: Plagl1 is not expressed in the Rybp-/- during in vitro cardiac differentiation 
Relative gene expression analysis of Plagl1 during in vitro cardiac differentiation by qRT-PCR 
analysis. The presented values are averages of three independent experiments; error bars 
indicate standard deviation. Values indicated by asterisks significantly differed in the Rybp-/- 




















4.3 PLAGL1 is not detectable at protein level either in the Rybp null mutant cells at all 
time points of in vitro cardiac differentiation. 
In order to investigate whether PLAGL1 is detectable during any time point of cardiac 
differentiation, we performed immunocytochemical analysis with samples derived from d0, d2, 
d7, d10, d14 and d21 of in vitro cardiac differentiation from the wild type and Rybp-/- cultures. 
The samples were stained for PLAGL1 with anti-PLAGL1 antibody (methods 3.3.4), and the 
pictures were taken using Olympus LSM confocal microscope. Our results defined that 
PLAGL1 protein levels corelated to the mRNA levels detected by qRT-PCR (Figure 17) in the 
wild type cells. PLAGL1 staining was detectable at d7 (Figure 18A) from the analysed time 
points and the PLAGL1 signal was the highest at d14 CMC stage (Figure 18A). As expected, 
PLAGL1 was not detected at all time points of in vitro cardiac differentiation in the Rybp null 
mutant cultures revealing that PLAGL1 expression was absent in the Rybp null mutant cultures 




















Figure 18: PLAGL1 is not detectable in the RYBP null mutant cells during in vitro cardiac 
differentiation 
Immunocytochemical analysis of PLAGL1 (Red) in the (A) wild type and (B) Rybp-/- null mutant 
cells derived from d0, d2, d7, d10, d14 and d21. DAPI (blue) was used to stain the nuclei. The 
indicating time points are represented in top. Olympus Confocal IX 81, Obj: 60x; Scale bar: 
100 µm. 
 
4.4 Overview of the Plagl1 genomic locus 
To unravel the molecular mechanism behind the downregulation of Plagl1 in the Rybp null 
mutant cells during cardiac differentiation, we analysed the Plagl1 genomic locus 
(Chr10:13090832-13131694 bp) for the position of promoters, regulatory RNAs and potential 
splice variants. The Plagl1 genomic locus was downloaded in FASTA format from ENSEMBL 
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(ENSMUSG00000019817) and the respective position of the coding exons were mapped 
according to ENSEMBL and the downloaded mRNA sequences from ESTs. Based on previous 
publications and by carefully mapping the regulatory regions for promoter regions and different 
ncRNAs we have reconstructed the Plagl1 genomic locus. The Plagl1 genomic locus consists 
of three promoter regions P1, P2 and P3, eleven exons and two ncRNAs Hymai and Plagl1 
intronic transcript (Plagl1it) (Figure 19). The P1 promoter, which harbours demethylated CpG 
islands is the site of imprinting of the Plagl1 locus. The P2 promoter which lies 30 kb upstream 
to the transcription start site (TSS) is previously identified to express Plagl1 biallelically and 
functions only in disease conditions. The P3 promoter contains variable enhancer elements like 
a TATA box and several consensus binding-sites for key lineage specific transcription factors 
such as NKX2-5, MEF2C and TBX5. Hymai and Plagl1it ncRNAs are imprinted and expressed 
downstream to the P1 promoter. Exons 10 and 11 code for the full length PLAGL1 protein. 
PLAGL1 protein contains seven C2H2-type zinc finger domains at the amino terminal of the 
protein, from the amino acids 1 to 210. This region also encompasses two nuclear localization 
signals (NLS) along the zinc finger domains. PLAGL1 also contains proline and glutamine rich 
regions at the carboxyl terminal (residues 220 to 444) (Figure 19). 
 
Figure 19: Schematic illustration of the Plagl1 genomic locus 
Schematic representation of the Plagl1 genomic locus. Exons are represented with grey bars; 
The three promoters P1, P2 and P3 are marked in blue ovals; The two ncRNA, Hymai ncRNA 
and Plagl1it are represented with orange rectangle. Abbreviations: kb: kilobase, bp: base pair, 
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4.5 The expression of the two ncRNAs Hymai and Plagl1it are also affected in the Rybp 
null mutant CMCs during cardiac differentiation 
Since our results determined that all splice variants of Plagl1 are not detected in the Rybp null 
mutant cells during the time course of in vitro cardiac differentiation, we wondered if the two 
ncRNAs Hymai and Plagl1it are also affected in the Rybp null mutant CMCs. Gene expression 
analysis using qRT-PCR determined that the expression kinetics of both Hymai and Plagl1it in 
the wild type cultures resembled the expression kinetics of Plagl1 (Figure 20A and B). Hymai 
(Figure 20A) and Plagl1it (Figure 20B) expression could be first detected by d2, EB formation 
stage and the expression peaked by d14 suggesting that the two ncRNAs might function in the 
regulation of Plagl1. The high expression levels of both ncRNAs at d14 is also indicative of 
their potential functions during CMC development.  
Both Hymai and Plagl1it expression in the Rybp null mutant cells were also affected at all the 
analysed time points (Figure 20A and B). Unlike Plagl1, Hymai and Plagl1it ncRNA 
expression was detected at low levels in the Rybp null mutant CMCs further indicating the 
significant effect of the loss of Rybp in Plagl1 regulation. 
 
 
Figure 20: Hymai and Plagl1it expressed at low levels in Rybp-/- at all examined stages of in 
vitro cardiac differentiation 
Relative gene expression analysis of Hymai (A) and Plagl1it (B) during in vitro cardiac 
differentiation by qRT-PCR analysis. The presented values are averages of three independent 
experiments; error bars indicate standard deviation. Values indicated by asterisks significantly 
























4.6 Multiple splice variants of Plagl1 can be transcribed from monoallelic and biallelic 
promoters 
As the Plagl1 mRNA was not expressed in the Rybp null mutant cells at any of the examined 
time points of in vitro cardiac differentiation (results 4.2), we further performed detailed in 
silico analysis of the various splice variants that are transcribed from the Plagl1 genomic locus. 
We have also identified the corresponding promoters producing protein coding transcripts and 
the promoters that can be active during cardiac differentiation. cDNA sequences were 
downloaded from NCBI (https://www.ncbi.nlm.nih.gov/nuccore/) and the transcripts were 
aligned with ClustalW tool in BioEdit programme.  
The schematic representation presented on Figure 21 was generated based on the analyses with 
representative NCBI accession I.D of the cDNA transcripts. The position of the Plagl1 
promoter regions is mutually exclusive to the emerging cDNAs. Our analysis showed that 
FJ425893.1 emerge from the P2 promoter, NM_009538.2, NM_009538.3, NM_001364643.1, 
NM_001364644.1, NM_001364645.1, BC141284.1 and AF147785.1 emerge from the P1 
promoter and X95504.1, AA919394.1 and AF324471.1 emerge from the P3 promoter. 
NM_009538.2 and NM_009538.3 are mostly similar and differ only in their 5’ region of exon 
8 coding. NM_001364643.1, NM_001364644.1 and NM_001364645.1 are also similar splice 
variants with NM_001364644.1 harbouring an alternate splice site within exon 11. 
NM_001364645.1 variant differs from NM_001364644.1 by harbouring exon 8 additionally. 
The identified splice variants may have tissue and disease specific expression. We also 
conclude that all the three promoters can produce protein coding transcripts since the last two 





Figure 21: Plagl1 can be expressed by mono and biallelic promoters 
Schematic representation of the various splice variants of Plagl1 based on ESTs deposited in 
EST database (methods 3.4.2). The NCBI accession numbers (NCBI ACC #) are presented on 
the left side, the corresponding promoters from where the transcripts are transcribed from are 
presented at the right side. Splice variants are shown in grey boxes in the middle. The numbers 
in the boxes represent corresponding exons. 
4.7 Splice variants of Plagl1 are transcribed from P1 and P3 promoters during in vitro 
cardiac differentiation 
To gain further insights about which promoters are active during the time course of in vitro 
cardiac differentiation we performed gene expression analysis using primers specific to the 
exons that are distinctive to the transcripts produced from the alternative promoter regions. We 
used primers specific to exon 1 and 2 (hereafter mentioned as Plagl1 1/2) to check the 
expression from Plagl1 P2 promoter, primers specific to exon 6 and 7 (hereafter mentioned as 
Plagl1 6/7) to check the expression from Plagl1 P1 promoter. The P2 promoter produces 
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expression of Plagl1 as the P1 promoter is the site of imprinting and all genomic products 
downstream to P1 are imprinted. The Plagl1 P3 promoter is situated immediately upstream to 
the last two exons which code for the full length PLAGL1 protein. As these two exons are 
present in all the transcripts, we couldn’t make primers specific to check the activity of only 
P3 promoter. We used primers specific to exon 10 and 11 as a universal primer which can 
detect the expression of all the splice variants of Plagl1 together. 
 QRT-PCR analysis using Plagl1 6/7 primers in the wild type cultures showed that Plagl1 
expressed weakly until day 7 and its expression levels induced to over 100 folds when 
compared to the wild type d0 (Figure 22A). The expression of Plagl1 using Plagl1 10/11 
(Figure 22B) showed up to 400 folds change increase in d14 as opposed to the 100 folds 
increase in the d14 Plagl1 6/7 suggesting that both Plagl1 P1 and P3 promoters could be 
presumably active during in vitro cardiac differentiation (Figure 22B). Using primers specific 
to Plagl1 1/2 we did not get any signal in the wild type cells (data not shown) suggesting that 
the P2 promoter might not be active during cardiac development and could only cause biallelic 
expression of Plagl1 in disease states such as the Transient neonatal diabetes mellitus (TNDM) 
(Valleley et al., 2007). In the case of the Rybp-/- cells, we could not detect Plagl1 expression 
using any primer sets. 
 
Figure 22: Plagl1 is expressed from both P1 and P3 promoters during in vitro cardiac 
differentiation 
Relative gene expression analysis of Plagl1 using primers specific to (A) exon 6/7 and (B) exon 
10/11 during in vitro cardiac differentiation. The presented values are averages of three 
independent experiments; error bars indicate standard deviation. Values indicated by asterisks 
significantly differed in the Rybp-/- compared to Rybp+/+ by the statistical method two-way 
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4.8 Two isoforms of the PLAGL1 protein are detectable during in vitro cardiac 
differentiation 
In order to further characterize the isoforms of the PLAGL1 protein, that are expressed during 
in vitro cardiac differentiation, we performed Western blot analyses. Protein cell lysates were 
derived from the indicated points of in vitro cardiac differentiation and 20 µg of the total protein 
from each time point was loaded into each well for Western blot analysis (methods 3.3.1). Our 
results showed that PLAGL1 signals correlated to the mRNA expression levels (methods 
3.1.1). PLAGL1 was hardly detectable until d2. The first time point when PLAGL1 was clearly 
detectable was at day 7, which corresponds to the stage of cardiac progenitor formation stage 
(Figure 23). The expression peaked by d14, corresponding to the time of cardiomyocyte 
formation. At d7 and d10 the two major isoforms of PLAGL1: PLAGL1 a (NCBI Accession: 
NP_033564.2, 79 kDa) and PLAGL1 b (NCBI Accession: NP_001351572.1, 76 kDa) can be 
seen indicating that just two isoforms of PLAGL1 are expressed during in vitro cardiac 
differentiation (Figure 23). In d14 and d21 several bands of PLAGL1 protein were obtained 
which we further analysed for potential post-translation modification of PLAGL1 (Figure 23).  
 
Figure 23: Two isoforms of PLAGL1 are expressed during in vitro cardiac differentiation 
Western blot analysis detected the two isoforms of PLAGL1 protein: PLAGL1 a and PLAGL1 
b can be seen clearly in d7 and d10. Protein lysates from d21 Rybp null mutant CMCs was 
used as the negative control. Lysate from flag tagged PLAGL1 over-expresser in HEK293T 
cells was used as a positive control. β Tubulin was used as an internal loading control to 
monitor the kinetics of PLAGL1 during the time course of cardiac differentiation. The 
respective molecular weights of both PLAGL1 and β Tubulin are indicated at the right. 

















4.9 PLAGL1 undergoes post translational degradation during CMC formation 
Analysis of the PLAGL1 protein in wild type differentiated CMCs by Western blot displayed 
multiple bands of PLAGL1 protein in d14 and d21 cardiac differentiated cell lysates (Figure 
23). The highest two bands correspond to the isoforms of PLAGL1 protein: PLAGL1 a and 
PLAGL1 b which can be seen at 79 kDa and 76 kDa respectively (Figure 23). We wondered if 
the additional bands between 76 kDa and 51 kDa were post translational modifications of the 
PLAGL1 isoforms. In order to identify if PLAGL1 undergoes post translational modifications 
during cardiac differentiation we performed experiments with Cyclohexamide (CHX) a 
translational inhibitor and MG132 a protease inhibitor (methods 3.3.2). In brief, we 
differentiated ES cells to form CMCs in vitro for 14 days and treated the cells with media 
supplemented with 75 µg/ml concentration of CHX. Cells were harvested and lysed at every 
hour until 6 hr. Our results determined that PLAGL1 was undergoing post translational 
degradation and formed a stable 51 kDa size protein upon CHX treatment (indicated in red 
arrow, Figure 24A). Next, we performed the same experiment by treating the cells with 10 µM 
MG132. Upon MG132 treatment the 51 kDa degraded band was not formed due to the 
inhibition of protease activity and the two isoforms PLAGL1 a and PLAGL1 b were detected 
stronger (Figure 24B). These results demonstrated that PLAGL1 underwent degradation by 

















Figure 24: PLAGL1 undergoes degradation upon CHX treatment  
(A)Western blot analysis displaying PLAGL1 modifications after treatment with 75 µg/ml CHX 
suplemented to wild type d14 CMCs along with media. Both isoforms of the PLAGL1 protein 
degraded to a stable 51 kDa size protein. (B) Western blot analysis displaying PLAGL1 
modifications after treatment with 10 µM MG132 suplemented to wild type d14 CMCs along 
with media. MG132 treatment caused inhibition of protease activity resulting in accumulation 
of the two PLAGL1 isoforms. β-Tubulin was used as an internal loading control. The respective 
molecular weights of both PLAGL1 and β -Tubulin are labelled in kDa at the right. 
Abbreviations: CHX: Cyclohexamide, hr: hour, Untrans HEK: Untransfected human 
embryonic kidney cells, kDa- kilo Daltons, β TUB: β Tubulin. 
4.10 PLAGL1 has a degron site immediately after the Serine-Threonine phosphorylation 
sites at the N-terminal 
In order to identify the site of degradation and undertsand the machanism by which PLAGL1 
protein undergoes post-translational degradation, we analysed the PLAGL1 amino acid 
sequence for possible degron sites and motifs. Our analysis with bioinformatic tools based on 
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previously indicated conserved degron motifs (methods 3.4.3) determined that PLAGL1 has 2 
NLS in the amino terminal of the protein. This region also has numerous serine-threonine sites 
that can get phosphorylated and harbour polyubiqutination for protease activity (Figure 25A). 
Our analysis also determined that S223-T232-S233 posses a degron site immediately after the 
rapid serine-throeonine phosphorylation sites which can aid protease activity (Figure 25A). 
The supposed cleavage of PLAGL1 protein at the S223-T232-ST233 degron site will result in 




Figure 25: NLS and degron motifs in the N-terminal of PLAGL1  
(A) Schematic representation of NLS, serine-threonine phosphorylation and degron sites in the 
PLAGL1 amino acid sequence. The two NLS sequences are indicated in blue boxes and the 
degron site is indicated in black bar. The serine-threonine phosphorylation sites in PLAGL1 
protein are indicated in red. (B) Schematic representation of PLAGL1 protein fragmentation 
after post-translational degradation at the degron site (S223-S233). Abbreviations: NLS: 
nuclear localization signal, s: serine, t: threonine, y: tyrosine, kDa: kilo Daltons. 
4.11 PLAGL1 and RYBP are co-expressed in the nuclei of the differentiating cardiac 
cultures 
The fact, that there is no Plagl1 in the Rybp null mutant ES cells and differentiated CMCs made 
us think whether Plagl1 is regulated by RYBP. To deepen our understanding about the 
relationship between Rybp and Plagl1, we next analysed available in vivo evidence to see if 
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Rybp and Plag11 are expressed in the same tissue types of the developing mouse embryo. We 
collected data containing RNA in situ hybridization experiments from existing publications 
about the expression pattern of Rybp and Plagl1 in various tissue types during mouse 
embryonic development. This analysis revealed that Rybp and Plagl1 co-expressed in several 
tissue types specific to the central nervous system, heart and eye (Table 2). We previously 
established that Rybp expressed moderately in the E8.5 and E9.5 heart (Ujhelly et al., 2015). 
RNA in situ hybridization and Northern blot analysis showed that Plagl1 expressed immensely 
from as early as E7.5 heart until adulthood in a chamber-restricted pattern (Yuasa et al., 2010). 
These data suggested that the two proteins might be present in the same cells during CMC 
differentiation. 
Therefore, to examine the subcellular localization of RYBP and PLAGL1 we co-stained the 
wild-type cardiac cultures, with anti-RYBP and anti-PLAGL1 antibodies. We performed 
immunostaining on cells derived during in vitro cardiac differentiation (i.e., d0, d2, d7, d10, 
d14 and d21). At d0, RYBP was observed both in the nuclei and cytoplasm of the wild type 
cells (Figure 26). At later time points RYBP was predominantly seen in the nuclei and 
expressed persistently at all the observed time points of in vitro cardiac differentiation (Figure 
26). On the other hand, in the wild type cells PLAGL1 was not detected at early time points d0 
and d2 (Figure 26). PLAGL1 signals were first observed from d7 and its expression gradually 
increased as differentiation proceeded with highest observed expression at d14 (Figure 26). At 
d7, which represents an early cardiac stage showed a mixed population of both PLAGL1 
expressing and non-expressing cells suggesting that the cells are in heterogenous state of 
differentiation and PLAGL1 could start to be expressing in the differentiating cells only (Figure 
26). These data suggested that the RYBP and PLAGL1 prominently co-expressed when cells 




Figure 26: RYBP colocalized with PLAGL1 in the nuclei of differentiating cardiac cultures 
Immunocytochemical analysis for the subcellular localisation of RYBP and PLAGL1 of wild 
type cultures during d0, d2, d7, d10, d14 and d21 time points of in vitro cardiac differentiation. 
Immunostainings: blue: DAPI (nuclei), green: RYBP, red: PLAGL1. Olympus Confocal IX 81, 














4.12 Plagl1 expression is first detected at early progenitor stage during in vitro cardiac 
differentiation 
To determine the earliest time point, when Plagl1 first appears in the differentiated cardiac 
cultures and to gain insights into the possible relationship between RYBP and PLAGL1, we 
checked the expression of Rybp and Plagl1 between d2 and d7 time points. We performed a 
new experimental setup (methods 3.1.2) differentiating mouse ES cells until the early phase of 
in vitro cardiac differentiation deriving samples every day from d3, d4, d5 and d6 of in vitro 
cardiac differentiation. The EBs from hanging drops on d2 were plated into 6 cm plates for 
further gene expression analysis by qRT-PCR and in 24 well plates for protein localisation 
studies by ICC (methods 3.1.2). Rybp expressed persistently while Plagl1 expression elevated 
after d3, and the expression increased for over 2 folds from d4 in the wild type cultures. As 
expected, Plagl1 expression was not detected at any time point in the Rybp-/- cells (Figure 27A, 
B). From our previous results, we knew that RYBP was detected uniformly in the nuclei of d2 
EBs (Figure 26). ICC experiments using d3, d4, d5 and d6 EBs revealed that RYBP was 
detected strongly in the outgrowth of the attaching EBs after d3 (Figure 27C e, f, g and h). 
PLAGL1 was more explicitly detected from d4 in the wild type cells, which is likely to 
correspond to the earliest days of progenitor formation stage during in vitro cardiac 
differentiation (Figure 27C j). The number of PLAGL1 positive cells gradually increased from 
d4 and more PLAGL1 positive cells were detected in d5 and d6 (Figure 27C k and l). From d4, 
RYBP and PLAGL1 co-expressed in the nuclei and the intensity of PLAGL1 signals varied in 
the heterogenous population of differentiating cells. The PLAGL1 expressing cells were mostly 
detected in the outgrowth of the attaching EBs, the place from where differentiation proceeds 








Figure 27: PLAGL1 expression is induced during the early progenitor stages of cardiac 
differentiation 
(A, B) Relative gene expression analysis of Rybp and Plagl1 by qRT-PCR in samples derived 
from in vitro cardiac differentiation at d0, 2, 3, 4, 5 and 6 days of cardiac differentiation. The 
presented values are averages of three independent experiments; error bars indicate standard 
deviation. Values indicated by asterisks significantly differed in the Rybp-/- compared to 
Rybp+/+ by the statistical method two-way ANOVA (****p < 0.0001). (C) Immunocytochemical 





















differentiated samples. Immunostainings: blue: DAPI (nuclei), green: RYBP, red: PLAGL1. 
Olympus Confocal IX 81, Obj.: 60 x; Scale bar: a-p: 100 µm. Abbreviations: d: day. 
4.13 Plagl1 promoters contain distinctive regulatory elements  
Since our preliminary results suggested that Plagl1 might be a downstream target of RYBP, 
we next investigated the regulatory elements in the Plagl1 promoters. The Plagl1 promoter 
sequences were downloaded from ENSEMBL (ENSMUSG00000019817) based on the 
previously identified sequences in Platas et al., 2012 and Platas et al., 2013. The promoter 
sequences were analysed for presence of CpG islands and TATA box (Figure 28). The P1 
promoter (4612 bp), which is the site of imprinting contains long stretch of CpG island (1673 
bp) that covers 27.5% of the promoter region. The P2 promoter which produces biallelic Plagl1 
transcripts and active only in disease conditions, has a 655 bp long CpG island whereas the P3 
promoter does not contain any CpG islands. The P1 promoter contains a 14 bp long TATA box 
(TACAGTTTTTTATAC) away from the CpG island (Figure 28). The P2 promoter does not 
contain any TATA box but contains three E-box consensus sequences (CACGTG and 
CAGCTG) which is not found in P1 and P3 promoters (Figure 28). The P3 promoter contains 
a 67 bp long TATA box at the middle of the promoter region (Figure 28). The identification of 
these regulatory positions indicated potential regulatory mechanisms at these promoters also 
emphasizing the possible mechanism by which RYBP could regulate these promoters. RYBP 
containing ncPRC1s were previously identified to bind at the CpG islands (Farcas et al., 2012) 
and RYBP was shown to associate with consensus binding E-box binding homeobox factors 






Figure 28: P1 and P2 promoters contain CpG islands and only P1 and P3 promoters have 
TATA box 
Schematic representation of the regulatory elements in the Plagl1 P1, P2 and P3 promoters. 
The CpG islands (Green box) positions were identified from DBCAT 
(http://dbcat.cgm.ntu.edu.tw) and the positions of TATA box (Blue box) and E-box (light brown 
box) motifs were identified by TRANFAC (https://genexplain.com/transfac/). The labels for the 
identified regulatory elements in the Plagl1 promoters are presented at the top. 
4.14 RYBP activates the Plagl1 P1 and P3 promoters 
In order to elucidate if RYBP can directly influence the activation of Plagl1 expression via its 
promoters, we performed luciferase reporter assays using reporter constructs containing Plagl1 
P1, P2 and P3 promoters. To investigate this hypothesis, we cloned a 4612 bp long Plagl1 P1 
promoter region encompassing exon 4 and P2 promoter encompassing exon 1 into pGL4.20 
vectors. The promoter constructs were then transiently transfected into HEK293T cells in 
combination with RYBP cDNA constructs (Arrigoni et al., 2006) (methods 3.1.4). The protein 
cell lysates from the transfected cells were harvested 48 hrs after transfections and the 
luciferase levels were measured using a luminometer after inducing the luciferase signals with 
substrate. All three promoters P1, P2 and P3 containing luciferase constructs produced modest 
level of luciferase signals due to the endogenous transcription factors in HEK293T cells. The 
luciferase activity of the three promoters co-transfected with RYBP were normalized to the 
base level luciferase signal of the single transfected P1, P2 and P3 promoter constructs, 
respectively in all consecutive experiments. Our results showed that when co-transfected with 
RYBP, Plagl1 P1 and P3 promoter luciferase levels increased for up to 1.6-fold and 2.5-fold 
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activation of the promoters by RYBP (Figure 29). In the contrary, the luciferase levels 
produced by P2 promoter construct got marginally reduced to 0.8-fold under the influence of 
RYBP indicating that this P2 promoter is not activated, but perhaps mildly repressed by RYBP. 
 
Figure 29: RYBP overexpression activated P1 and P3 promoters and repressed the P2 
promoter 
HEK293T cells were transfected with 2.5 µg of Rybp and 5 µg of Plagl1 P1, P2 and P3 
promoter containing luciferase reporter constructs. Luciferase activity of the transfected cell 
lysates were measured 48 hours after transfection. Values are expressed as fold changes of 
luciferase activity normalized to P1, P2 or P3 single transfected signals. The presented values 
are averages of three independent experiments; error bars indicate standard deviation. Values 
indicated by asterisks significantly differed from the value taken as 1 according to the 
statistical method one-way ANOVA (****p < 0.0001). 
4.15 The activation of Plagl1 P1 and P3 promoters by RYBP is polycomb independent  
Since RYBP was originally identified as a polycomb protein and purified as a core member of 
the ncPRC1s, we wondered whether RYBP activates Plagl1 P1 and P3 promoters in a 
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4.15.1 A small molecule- PRC1 inhibitor did not attenuate the activation by RYBP 
at the P1 and P3 promoters 
In order to unravel whether RYBP activates Plagl1 P1 and P3 promoters in a polycomb 
dependant or independent manner, HEK293T cells were transiently transfected with all three 
Plagl1 promoter containing luciferase reporter constructs in combination with RYBP 
overexpression construct. 16 hrs after transfection the cells were treated with 50 µM of 
PRT4165 (PRC1 inhibitor) supplemented with media (methods 3.1.5). To let the inhibitory 
effect of PRT4165 develop, the transfected cells were cultured further for another 24 hours 
under humidified conditions and finally harvested for their protein cell lysates. Luciferase 
reporter assay was carried out using single transfected promoter constructs as normalization 
controls as described earlier (results 4.1.4). Our results showed that RYBP overexpression 
could still activate Plagl1 P1 (1.5-fold) and P3 (4.43-fold) promoters in the presence of the 
PRC1 inhibitor (Figure 30). Moreover, in these conditions the originally repressed Plagl1 P2 
promoter did not present any significant activity when compared to the single transfected 
control suggesting that the repressive activity of RYBP at the P2 promoter was reversed by 
PRT4165. These results suggested that RYBP activated Plagl1 P1 and P3 promoters in a 







Figure 30: RYBP overexpression activates P1 and P3 promoters in a PRC1 independent 
mechanism. 
HEK293T cells were transfected with 2.5 µg of Rybp and 5 µg of Plagl1 P1, P2 and P3 
promoter containing luciferase reporter construct. Transfected cells were treated with 50 µg 
of PRT4165 supplemented with media after 16 hrs after transfection. Luciferase activity of the 
transfected cell lysates were measured 48 hours after transfection. Values are expressed as 
fold changes of luciferase activity normalized to P1, P2 or P3 single transfected signals 
respectively for samples containing the respective promoters. The presented values are 
averages of three independent experiments; error bars indicate standard deviation. Values 
indicated by asterisks significantly differed from the value taken as 1 according to the 
statistical method one-way ANOVA (***p < 0.001). 
4.15.2 RING1 does not synergistically function with RYBP at the Plagl1 P1 and P3 
promoters  
RYBP and RING1 are core members of the ncPRC1s, physically interacting with each other 
(Gao et al., 2012). After elucidating that a potent PRC1 inhibitor PRT4165 did not affect the 
activation of the P1 and P3 promoters by RYBP, indicating that the activation of the two 
promoters by RYBP acts in a polycomb independent manner, we further confirmed this by 
checking if RING1 can act synergistically with RYBP. In these experiments, HEK293T cells 
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were transiently transfected with all three Plagl1 promoter containing luciferase reporter 
constructs in combination with a concomitant RYBP and RING1 overexpression. Luciferase 
reporter assay was carried out using single transfected promoter constructs as normalization 
controls as described earlier (results 4.1.4). Our results determined that RING1 could not 
elevate the activation signals of both P1 and P3 promoters by RYBP (Figure 31A and B). The 
activity of RING1 itself caused mild increase in the luciferase levels in both P1 (1.7-fold) and 
P3 (1.6-fold) promoters although the measured levels never reached the level achieved by 
RYBP itself. In case of the P2 promoter, which is in a maintained repressed state during normal 
developmental conditions, showed an unexpected increase of 2.8-fold by RING1 itself when 
compared to the P2 promoter control disclosing the possible role of RING1 in PLAGL1 related 
disease conditions connected to P2 promoter (Figure 31 C). These results further validate the 
previous results suggesting a polycomb independent activation of the P1 and P3 promoters by 
RYBP and at the same time pinpointing that the mild repressive effect of RYBP on the P2 










Figure 31: RING1 did not enhance the activation potential of RYBP at P1 and P3 
promoters 
HEK293T cells were transfected with 2.5 µg of Rybp, 2.5 µg of pcDNA3.1 Ring1 FLAG and 5 
µg of Plagl1 P1, P2 and P3 promoter containing luciferase reporter construct. Luciferase 
activity of the transfected cell lysates were measured 48 hours after transfection. Values are 
expressed as fold changes of luciferase activity normalized to P1, P2 or P3 single transfected 
signals respectively for (A, B and C) respectively. The presented values are averages of three 
independent experiments; error bars indicate standard deviation. Values indicated by asterisks 
significantly differed from the value taken as 1 according to the statistical method one-way 
ANOVA (**p < 0.01; ****p < 0.0001). 
4.15.3 Existing ChIP-seq analysis revealed a polycomb independent binding of 
RYBP at the P3 promoter 
In order to have a deeper understanding of our results generated from the luciferase reporter 
assays we analysed existing ChIP-seq binding datasets of RYBP and ncPRC1 core factor RNF2 
in Plagl1 locus from both ES cells and cardiac progenitor cells (CPCs). ChIP-seq raw data 
were downloaded as BEDGRAPH files for RYBP (ES cells: GSM4052120; CPC: 
GSM1657391) and RNF2 (ES cells: GSM4052131; CPC: GSM1657390) and analysed for 
binding peaks at the Plagl1 locus using IGV programme (methods 3.4.7). The files were 
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analysed to their respective experimental reference genome annotations i.e., mm10 for ES cells 
and mm9 for CPCs as disclosed by the authors. This analysis revealed binding of RYBP and 
RNF2 at P1 and P2 promoters and not at the P3 promoter in ES cells (Figure 32). Since the 
PRC1s mediated regulatory functions have an affinity to bind to the CpG islands, the presence 
of CpG islands in P1 and P2 promoters (Figure 32) can explain the binding of both RYBP and 
RNF2 at these promoters as well as lack of binding at the P3 promoter. Plagl1 is not expressed 
in ES cells and hence the binding of RYBP and RNF2 at P1 and P2 promoters suggests a PRC 
mediated repression of these promoters. The P3 promoter contains a ∽70 bp long TATA box 
(Figure 32) and surrounded with consensus sites for lineage specific transcription factors and 
hence might not express Plagl1 in ES cells. 
In CPCs both RYBP and RNF2 maintain strong binding at the P2 promoter as the P2 promoter 
is active only during abnormal conditions. At the P1 promoter both RYBP and RNF2 are 
dispersedly bound suggesting a weak binding of these factors at this promoter. At the P3 
promoter RYBP showed adequate binding (indicated in red arrow) independent to RNF2 
binding suggesting a direct activity of RYBP to regulate Plagl1 expression via P3.  
Since Plagl1 expressed from the CPCs stage of cardiac differentiation (Figure 17) the direct 
binding of RYBP at the P3 promoter in CPCs and not in ES cells together with the luciferase 
reporter assays (Figures 29, 30 and 31) gave a clear indication that RYBP indeed activates this 




Figure 32: RYBP binds at the P3 promoter independent to RNF2 binding in CPCs and not 
in ES cells 
Published ChIP-seq raw files of RYBP and RNF2 were downloaded from experiments 
generated from ES cells and CPCs. The downloaded files from Geo accession viewer 
(https://www.ncbi.nlm.nih.gov/geo/) under the IDs RYBP (ES cells: GSM4052120; CPC: 
GSM1657391) and RNF2 (ES cells: GSM4052131; CPC: GSM1657390) were processed in 
Integrative genome viewer (IGV). Binding peaks are displayed for RYBP (Blue) and RNF2 
(Green) at 0-50 data range in both ES cells and CPCs at Plagl1 locus (displayed on top) with 
indicative promoter and ncRNA regions. The binding of RYBP at P3 in CPCs is indicated in 















4.16 RYBP did not activate the P1 and P3 promoters synergetic with E2F and YY1 
transcription factors 
After identifying that RYBP activates Plagl1 P1 and P3 promoters in a polycomb independent 
manner we were wondering the possible mechanism by which RYBP activates the two 
promoters. RYBP was previously identified to activate Kdm2b expression in ES cells by 
associating with pluripotency factor POU domain pluripotency factor 1 (POUF51, classically 
called as OCT4) (Li et al., 2017). Since we already reported that the expression of pluripotency 
genes including Oct4 is not affected in the Rybp null mutant ES cells and Plagl1 expression is 
only first seen after cardiac lineage commitment we ruled out the possibility of RYBP 
activation mechanism via OCT4. The other reported activation mechanism by RYBP was 
demonstrated to bridge E2F (E2F2 and E2F3) and YY1 transcription factors to activate Cdc6. 
In order to investigate if RYBP can activate Plagl1 expression via E2F and YY1 we next 
performed luciferase reporter assay by co-transfecting HEK293T cells with the P1, P2 and P3 
luciferase constructs in combination with RYBP, E2F2, E2F3 and YY1 overexpression. 
Luciferase assay was performed as mentioned earlier (methods 3.1.4). Our results determined 
that E2F2, E2F3 and YY1 could not elevate the activation levels of P1 and P3 promoters by 
RYBP (Figure 33A and C). Breaking down the results, in the case of the P1 promoter 
interestingly E2F2 could induce high level of activation. In cells transfected with only E2F3, 
YY1 and in different combinations of RYBP, E2F2, E2F3 and YY1 overexpression the 
luciferase levels of the P1 promoter did not exhibit any statistical differences (Figure 33A). In 
the P2 promoter, as expected RYBP caused a decrease in luciferase levels when compared to 
the P2 promoter control. Intriguingly single transfections and combinations of RYBP, E2F2, 
E2F3 and YY1 overexpression all resulted in the activation of the P2 promoter (Figure 33B). 
In the P3 promoter, single transfection with RYBP resulted in the highest activation of P3 and 
this activation did not get pronounced with the presence of E2F2, E2F3 or YY1 (Figure 33C). 
These results determined that RYBP is not activating Plagl1 P1 and P3 via interacting E2F and 
YY1. Interestingly RYBP could rather activate the P2 promoter in combination with E2F and 









Figure 33: E2F and YY1 transcription factors cannot elevate the activation of P1 and P3 
promoters in combination with RYBP 
(A and C) Luciferase reporter assay determined that E2F and YY1 cannot elevate the 
activation levels of P1 and P3 promoters by RYBP. (B) Luciferase reporter assay determined 
that E2F and YY1 increased the activation level of P2 promoter by RYBP. Values are expressed 
as fold changes of luciferase activity normalized to P1, P2 or P3 single transfected signals 
respectively for A, B and C respectively. The presented values are averages of three 
independent experiments; error bars indicate standard deviation. Values indicated by asterisks 
significantly differed from the value taken as 1 according to the statistical method one-way 




4.17 Hymai and Plagl1it overexpression did not affect the activity of RYBP at the Plagl1 
P1 and P3 promoters 
Next, we further dissected the possible mechanism by which RYBP activates Plagl1 P1 and 
P3 promoters, considering the potential contribution of the ncRNAs located in the Plagl1 
genomic locus. NcRNAs such as Xist, Meg3 and Bvht have been previously shown to 
transcriptionally regulate its target genes. The ncRNAs in the Plagl1 genomic locus Hymai and 
Plagl1it ncRNAs express similar to Plagl1 during cardiac differentiation. So we wondered if 
the two ncRNAs can synergistically act with RYBP. To test this hypothesis, we PCR amplified 
Hymai and Plagl1it from d14 differentiated wild type cDNA and cloned into pcDNA3.1 
overexpression vector (methods 3.2.3). The cloned fragments were verified by sequencing and 
were transiently transfected to HEK293T cells with the P1, P2 and P3 luciferase constructs in 
combination with RYBP, Hymai and Plagl1it overexpression. Luciferase assay was performed 
as described earlier (methods 3.1.4). Our results determined that neither Hymai nor Plagl1it 
could synergistically act with RYBP to enhance the activation levels on the Plagl1 P1 and P3 
promoters (Figure 34A, B and C). In brief, on the P1 and P3 promoters, Hymai (P1: 5.5-fold 
and P3: 11-fold) and Plagl1it (P1: 4.42-fold and P3: 3-fold) could exert activation compared 
to the activation of just RYBP (P1: 4-fold and P3: 3-fold) (Figure 34A and C). The activation 
levels of the P1 and P3 promoters induced by Hymai and Plagl1it were not increased in 
combination with RYBP when compared to the effects induced by just Hymai and Plagl1it. On 
the P2 promoter, the two ncRNAs displayed no significant changes in combination with RYBP 
(Figure 34B). Our results also suggested that the two ncRNAs did not affect the P2 promoter 














Figure 34: Hymai and Plagl1it did not enhance the activation levels of P1 and P3 promoter 
by RYBP 
Luciferase reporter assay determined that Hymai and Plagl1it cannot elevate the activity of 
RYBP at the (A) P1, (B) P2 and (C) P3 promoters. Values are expressed as fold changes of 
luciferase activity normalized to P1, P2 or P3 single transfected signals for A, B and C 
respectively. The presented values are averages of three independent experiments; error bars 
indicate standard deviation. Values indicated by asterisks significantly differed from the value 
taken as 1 according to the statistical method one-way ANOVA (**p < 0.01; ****p < 0.0001). 
4.18 RYBP activates the P3 promoter via NKX2-5  
In order to identify the mechanism by which RYBP could activate Plagl1 P1 and P3 promoter 
we next identified the minimum region required by RYBP to activate the promoter and 
combined with transcription factor binding sites (TFBS) analysis to detect the possible 
regulatory mechanism. Since the response to RYBP overexpression was higher in the P3 
promoter than the P1 and due to the presence of enhancer elements such as a 67 bp long TATA 
box as opposed to the relatively smaller TATA box in the P1 promoter, we utilized only the 
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 4.18.1 RYBP activates the 3’ region of the P3 promoter containing binding sites 
for NKX2-5 and MEF2C 
Therefore, to detect the RYBP responsive regions in the P3 promoter we made deletion mutant 
clones of this promoter by restriction digesting P3 at several sites and re-cloned them back into 
luciferase reporter constructs (methods 3.2.3). These sub-clones were transfected in 
combination with RYBP cDNA and transfected in HEK293T cells for luciferase reporter 
assays. Our results demonstrated a surge in the activation of 3’ half of the P3 promoter when 
compared to the full length and 5’ sub-clones of the P3 promoter (Figure 35C). Sub-clones f, 
g and h of the P3 promoter displayed high activation levels (∽ 20-folds) as opposed to the 5-
fold activation by just RYBP. To gain insights into the RYBP response elements present in 
these sub clones we performed TFBS analysis using TRANSFAC (Figure 35A and B). We 
identified the presence of three Nkx2-5 and one Mef2c binding sites, from which the first two 
Nkx2-5 and the Mef2c sites were at close proximity to the TATA box. Also, from clone d and 
e which contained the first two Nkx2-5 sites the activation levels were not as high as clone f, g 
and h suggesting that the third Nkx2-5 site have more response to RYBP (Figure 35C). 
Comparing the activation signals of clone e, f, g and h, the Mef2c site did not seem to affect 
the activation by RYBP whilst the presence of Nkx2-5 sites itself displayed higher activation 





Figure 35: Deletion mutants of the P3 promoter resulted in the 3’ fragments activated the 
highest by RYBP which contained NKX2-5 binding sites. 
Consensus binding sites for (A) NKX2-5 and (B) MEF2C procured from JASPAR database 
(http://jaspar.genereg.net). (C) Luciferase reporter assay using the various sub-clones of the 
P3 promoter labelled left to the schematic representation of the fragments. Clones containing 
regions 1-2.8 kb (a), 1-1.3 kb (b), 1-1.6 kb (c), 1.3-2.8 kb (d), 1.6-3.7 kb (e), 2.8-5.4 kb (f), 2.8-
3.7 kb (g) and 3.7-5.4 kb (h) of the P3 promoter were transfected in HEK293T cells with RYBP. 
Values are expressed as fold changes of luciferase activity normalized to P3 single transfected 
signals. The presented values are averages of three independent experiments; error bars 
indicate standard deviation. Values indicated by asterisks significantly differed from the value 
taken as 1 according to the statistical method one-way ANOVA (****p < 0.0001). 
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4.18.2 RYBP does not activate the P3 promoter via MEF2C consensus sites 
After identifying the presence of Nkx2-5 and Mef2c binding sites at the RYBP responsive 
regions in the P3 promoter, we further analysed the influence of these sites for activation by 
RYBP by performing site directed mutagenesis at these sites. Site directed mutagenesis was 
performed for the 3 Nkx2-5 and 1 Mef2c sites by as altering the sites to form HindIII and BamHI 
sites (methods 3.2.4). Single mutants (clone 1, 2, 3 and 4) harbouring mutation for either Nkx2-
5 or Mef2c and progressive mutation of the sites harbouring more than one mutation of the 
Nkx2-5 and Mef2c sites (clones 5, 6 and 7) were generated. The mutants were co-transfected 
with RYBP and luciferase reporter assay was carried out as mentioned earlier (methods 3.1.4). 
Our results showed the clones 1, 2 and 3 harbouring mutations for the 3 Nkx2-5 binding sites 
displayed loss of activity implying the sites important for activation by RYBP (Figure 36). The 
activation signal did not get attenuated by the mutation of Mef2c site in clone 4 and the 
luciferase activity was over 20-fold implying that RYBP could activate this clone and that the 
Mef2c site was not important for the activation of the P3 promoter by RYBP (Figure 36). The 
mutation of the Nkx2-5 and Mef2c binding sites (clone 5, 6 and 7) also displayed attenuated 
luciferase levels suggesting that Nkx2-5 site was indeed important for the activation of the P3 






Figure 36: Binding site mutants of P3 promoter harbouring different mutations of NKX2-5 
and MEF2C revealed that NKX2-5 is required for the activation of P3 by RYBP 
Luciferase reporter assay using the various mutants of the P3 promoter containing mutation 
for Nkx2-5 and Mef2c sites as indicated in the schematic representation. Clone 1 harbours 
mutation for the first Nkx2-5 site, clone 2 harbours mutation for the second NKX2-5 site, clone 
3 harbours mutation for the third NKX2-5 site, clone 4 harbours mutation for the MEF2C site, 
clone 5 harbours mutation for the first Nkx2-5 and the Mef2c site, clone 6 harbours mutation 
for the first two Nkx2-5 sites and the Mef2c site and clone 7 harbours mutation for all the sites. 
The mutants were transfected in HEK293T cells with RYBP. Values are expressed as fold 
changes of luciferase activity normalized to P3 single transfected signals. The presented values 
are averages of three independent experiments; error bars indicate standard deviation. Values 
indicated by asterisks significantly differed from the value taken as 1 according to the 
statistical method one-way ANOVA (****p < 0.0001). 
4.18.3 RYBP and NKX2-5 can synergistically activate the P3 promoter 
Next in order to further clarify if RYBP and NKX2-5 can synergistically activate the P3 
promoter we performed luciferase reporter assay co-transfecting HEK293T cells with P3 
promoter containing luciferase reporter and overexpression constructs for RYBP and NKX2-
5. For this assay we generated a NKX2-5 overexpression construct by cloning NKX2-5 





















Our results showed that NKX2-5 can itself activate the P3 promoter (10.5-fold) as opposed 
to the 3-fold activation by just RYBP (Figure 37). In combination with NKX2-5, the 
activation of the P3 promoter by RYBP reached 80-folds implying that both RYBP and 
NKX2-5 can synergistically function in the activation of the P3 promoter (Figure 37).  
 
Figure 37: NKX2-5 overexpression elevated the activation of P3 promoter by RYBP 
Luciferase reporter assay using the P3 promoter in combination with RYBP and NKX2-5 
revealed that the P3 promoter was activated extensively. Values are expressed as fold changes 
of luciferase activity normalized to P3 single transfected signals. The presented values are 
averages of three independent experiments; error bars indicate standard deviation. Values 
indicated by asterisks significantly differed from the value taken as 1 according to the 
statistical method one-way ANOVA (*p < 0.05; **p < 0.01). 
4.18.4 RYBP can interact with NKX2-5 protein 
Since all previous results indicated that NKX2-5 might mediate the effects of RYBP in the 
activation of Plagl1 P3, we next examined if RYBP could interact with the NKX2-5 protein 
itself. To test this hypothesis HEK293T cells were co-transfected with RYBP in combination 
with either RING1-FLAG, FLAG-NKX2-5, FLAG-MEF2C and FLAG-PLAGL1 
overexpression constructs. FLAG tagged RING1, an established interactor of RYBP (Garcia 
et al., 1999) in the ncPRC1s was used as the positive control in this experiment. Since the 
earlier experiments revealed that MEF2C might not affect the activation of P3 promoter by 
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RYBP, we used FLAG tagged MEF2C as a potent negative control along with the PLAGL1. 
Co-immunoprecipitation (Co-IP) was performed with anti-RYBP tagged agarose beads 
(methods 3.3.3) and the immunoprecipitates were run in Western blot (methods 3.3.1) and 
hybridised with anti-FLAG antibody. Our results demonstrated that RYBP can interact with 
NKX2-5 protein. In brief, the cell lysate controls showed bands for RING1 (51 kDa), NKX2-
5 (40 kDa), MEF2C (55 kDa) and PLAGL1 (81 kDa) upon hybridising with anti-FLAG 
antibody. In the immunoprecipitates, as expected RING1 was immunoprecipitated with 
RYBP (Figure 38). The presumed negative controls MEF2C and PLAGL1 were not 
immunoprecipitated by RYBP (Figure 38). These results demonstrated that RYBP interacted 
with NKX2-5 and this interaction is a novel finding which is vital for the activation of Plagl1 
expression. 
 
Figure 38: Co-immunoprecipitation revealed that RYBP interacts with NKX2-5 protein 
Co-IP was performed from cell lysates derived from HEK293T cells co-transfected with RYBP 
with either RING1-FLAG, FLAG-NKX2-5, FLAG-MEF2C and FLAG-PLAGL1. The input 
lysates are in the left and the IPs are presented in the right with indicating labels at the top. 
The size of the bands is represented left to blot. RYBP interacted with the RING1 (51 kDa, 
positive control) and NKX2-5 (40 kDa) indicated with red arrow. RYBP did not interact with 




4.18.5 RYBP bound at the NKX2-5 consensus at the P1 and P3 promoters in 
CMCs but not in ES cells 
We next performed chromatin-immunoprecipitation (ChIP) coupled with qRT-PCR to identify 
if RYBP can directly regulate the P3 promoter. ChIP was performed using EpiXplore ChIP kit 
(methods 3.2.2). The shearing of the chromatin was performed using a sonicator and the 
sheared chromatin were sustained at an average size of 200-800 bp (Figure 8, methods 3.2.2). 
The sheared chromatin was incubated overnight with anti-RYBP antibody and magnetic beads 
conjugated with mouse IgG (provided by the kit, details in methods 3.2.2). The bound 
chromatin was separated using a magnetic stand and eluted. The immunoprecipitated 
chromatin was eluted and used for qRT-PCR analysis using primers specific to the Nkx2-5 and 
Mef2c consensus sites. This experiment was performed with chromatin isolated from wild type 
ES cells (d0) and d7 differentiated CMCs. Since Plagl1 expression is not found in ES cells and 
only seen from the progenitor formation stage, d7 was used to identify the specific binding of 
RYBP at both the P1 and P3 promoter. 1% of the sheared DNA used for ChIP was used for the 
input control. The data was presented as input percentage by normalizing the Ct values of the 
ChIP to the respective adjusted input Ct values. Our results revealed that RYBP can bind at the 
Nkx2-5 consensus sites in both P1 and P3 promoter in the d7 but not in d0 as expected (Figure 
39). Since NKX2-5 is a cardiac transcription factor and not expressed in d0, the binding of 
RYBP at the Nkx2-5 sites in d7 differentiating CMCs also implies the reason for Plagl1 








Figure 39: RYBP bound at the Nkx2-5 sites at P1 and P3 promoter in the wild type d7 
differentiating CMCs and not in d0 ES cells. 
ChIP-qRT-PCR was performed with sheared chromatin derived from d0 and d7 wild type 
cultures using primers specific to Nkx2-5 and Mef2c consensus. Primers specific to the 
previously described Klf4 promoter was used a positive control. 
RYBP bound discretely at the Nkx2-5 sites at both P1 and P3 promoter in the d7 differentiating 
CMCs and not in ES cells. Values are presented as input percentage normalized to adjusted 
input Ct values. The presented values are averages of three independent experiments; error 
bars indicate standard deviation. Values indicated by asterisks significantly differed in the 
Rybp+/+ d7 compared to Rybp+/+ d0 by the statistical method two-way ANOVA (****p < 
0.0001). 
4.19 Hymai and Plagl1it synergistically functions with NKX2-5 to activate the P3 
promoter  
As Hymai and Plagl1it ncRNAs could not affect the activation of the P3 promoter by RYBP, 
we next wondered if the two ncRNAs could influence the activation of P3 by NKX2-5. 
HEK293T cells were co-transfected with P3 promoter containing luciferase reporter construct 
with either Hymai, Plagl1it, NKX2-5 overexpression or in combination with the ncRNA 
(Hymai or Plagl1it) along with NKX2-5 overexpression. Luciferase reporter assay was 
performed as mentioned earlier (methods 3.1.4). Our results showed that both Hymai and 
Plagl1it could act synergistic with NKX2-5 (Figure 40). In brief, both Hymai (8.5-fold) and 
Plagl1it (3-fold) could activate P3 promoter as determined in the earlier experiments (Figure 
40). NKX2-5 overexpression activated the P3 promoter (5.6-fold) and this activation got 





























results suggested that both Hymai and Plagl1it ncRNAs synergistically activate the P3 
promoter with NKX2-5 implying that the ncRNAs also function in this activation mechanism 
(Figure 40).  
 
Figure 40: Hymai and Plagl1it ncRNA can enhance the activation of P3 promoter by NKX2-
5. 
Luciferase reporter assay using the P3 promoter in combination with Hymai, Plagl1it and 
NKX2-5 revealed that the activation of the P3 promoter by NKX2-5 was enhanced significantly 
by both Hymai and Plagl1it. Values are expressed as fold changes of luciferase activity 
normalized to P3 single transfected signals. The presented values are averages of three 
independent experiments; error bars indicate standard deviation. Values indicated by asterisks 
significantly differed from the value taken as 1 according to the statistical method one-way 
ANOVA (*p < 0.05; ***p < 0.001; ****p < 0.0001). 
4.20 PLAGL1 is important for the formation of terminally differentiated CMCs and 
sarcomere organisation 
Plagl1 is required for the proper formation of heart in vivo (Yuasa et al., 2010). Rybp null 
mutant cardiac differentiated cultures, lack Plagl1 expression and could not form contracting 
CMCs. In order to characterize the functions of PLAGL1 during in vitro cardiac differentiation, 
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4.20.1 PLAGL1 co-expressed with CTNT in the differentiating CMCs  
To elucidate if the expression of Plagl1 admissible towards the formation of terminally 
differentiated CMCs, we performed ICC with wild type d7 and d14 differentiating CMCs co-
stained for PLAGL1 and cardiomyocyte marker CTNT. CTNT is a classical cardiomyocyte 
marker and component of thin filament structure of the sarcomere. ICC was performed as 
mentioned earlier (methods 3.3.4). From our results, CTNT staining was visualized in the 
nuclei and dispersed along the cell of the d7 differentiating CMCs (Figure 41b). Nuclear 
staining of CTNT is previously reported in maturing muscle murine cells (Asumda & Chase, 
2012). In d14 CMC cultures, CTNT staining was present in the cytoplasm (Figure 41f). 
PLAGL1 signals were strongly present in the cells that showed strong CTNT staining 
(indicated in white arrow, Figure 41d and h). These results determined that PLAGL1 and 
CTNT were co-expressed in the same differentiating CMCs and cells displaying strong CTNT 
staining also had strong PLAGL1 signals indicating the relevance of PLAGL1 expression 
towards the formation of terminally differentiated CMCs (Figure 41d and h). 
 
Figure 41: PLAGL1 and CTNT are co-expressed in the same differentiating CMCs 
Immunocytochemical analysis of PLAGL1 (c, g) and CTNT (b, f) in day 7 and 14 samples of in 
vitro cardiac differentiated. DAPI (a, e) was used to stain the nuclei. Both PLAGL1 and CTNT 
co-stained the same differentiating CMCs (highlighted with white arrow). Immunostainings: 
blue: DAPI (nuclei), green: RYBP, red: PLAGL1. Olympus Confocal IX 81, Obj.: 60 x; Scale 
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4.20.2 Sarcomere gene promoter regions contain consensus binding sites for 
PLAGL1 
Since the expression of PLAGL1 protein had relevance to the formation of terminally 
differentiated CMCs, we were curious whether PLAGL1 could be involved in regulating 
sarcomeric gene expression. In order to achieve this, we first performed a consensus motif 
search for PLAGL1 binding at the sarcomeric gene promoters. Promoter sequence of sarcomere 
thin filament markers Actc1, Tnnt2, Tnni3, Tpm1, Tpm4 and thick filament markers Myh7, 
Myom1, Ttn were downloaded from ENSEMBL (https://www.ensembl.org/index.html) in 
FASTA format based on the indicating promoter regions by the database. In case of more than 
1 indicating promoter region, the promoter immediately upstream to the TSS was considered. 
The sequences were then analysed for the binding of PLAGL1, NKX2-5, MEF2C and TBX5 
using JASPAR tool (http://jaspar.genereg.net). TFBS was performed by choosing consensus 
of these TFs from mouse (methods 3.4.5). The results were generated as binding scores with 
scores higher than 10 considered significant match to the experimentally identified consensus. 
This analysis resulted in several binding sites for PLAGL1, NKX2-5, MEF2C and TBX5 at 
each promoter region indicating that PLAGL1 could regulate these promoters parallel to 
NKX2-5, MEF2C and TBX5 which are already shown to affect the regulation of sarcomeric 







Figure 42: PLAGL1 can bind to the promoter of sarcomeric genes 
Motif search for TFBS of PLAGL1, NKX2-5, MEF2C and TBX5 at the sarcomeric promoters 
were analysed from JASPAR. The resulting binding score was used to generate Manhattan 
plot. The gene names and the indicating TFs are presented below. The binding strength is 
presented at the left with binding score higher than 10 considered significant (indicated by a 
dotted line). 
4.20.3 PLAGL1 can activate the Tnnt2 promoter 
Since our previous results indicated that PLAGL1 could potentially regulate the sarcomeric 
genes via their promoters, we tested this hypothesis by PCR amplifying and cloning Tnnt2 
promoter from genomic DNA derived from wild type ES cells (methods 3.2.3). The promoter 
was cloned into luciferase reporter constructs, verified by sequencing the fragment and co-
transfected into HEK293T cells with either NKX2-5, MEF2C or PLAGL1. NKX2-5 and 
MEF2C were previously shown to affect the regulation of sarcomeric genes and were used as 
positive controls. Luciferase reporter assay was performed as indicated earlier (methods 3.1.4). 
Both NKX2-5 (16-fold) and MEF2C (4-fold) could activate the Tnnt2 promoter as expected 
(Figure 43). PLAGL1 activated the Tnnt2 promoter over 14-folds elucidating that PLAGL1 
can activate the expression of sarcomeric genes via their promoters as analysed by Tnnt2 
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differentiation and that the loss of Plagl1 expression could affect differentiation by signalling 
sarcomere gene expression, which is vital for contractility. 
 
Figure 43: PLAGL1 activates sarcomeric thin filament marker Tnnt2 promoter 
Luciferase reporter assay using the Tnnt2 promoter in combination with NKX2-5, MEF2C and 
PLAGL1 revealed that the activation of the Tnnt2 promoter was enhanced significantly by 
PLAGL1. The activation of the Tnnt2 promoter by PLAGL1 was similar to the activity of the 
positive control NKX2-5 and higher than the activity of MEF2C. Values are expressed as fold 
changes of luciferase activity normalized to P3 single transfected signals. The presented values 
are averages of three independent experiments; error bars indicate standard deviation. Values 
indicated by asterisks significantly differed from the value taken as 1 according to the 
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RYBP is a member of the non-canonical polycomb repressive complex 1s (ncPRC1s), which 
are classically highlighted for their role as repressors (Garcia et al., 1999). As expected, genetic 
alterations of genes coding for polycomb proteins majorly resulted in the upregulation of genes 
in the mutant ES cells further confirming their role as epigenetic repressors. Recently, multiple 
studies have also revealed the downregulation of several genes in the polycomb mutant cells 
(Morey et al., 2013, 2015; Obier et al., 2015; Ujhelly et al., 2015; Zhao et al., 2020) For 
example, polycomb YY1 associated factor 2 (YAF2) is an ortholog of RYBP that shares over 
65% homology to RYBP. Knock out of YAF2 in mouse ES cells resulted in 351 genes 
upregulated and 146 genes downregulated in the Yaf2-/- cells (Zhao et al., 2018). Furthermore, 
knockdown of Polycomb group ring finger 2 (PCGF2 also called as MEL18) using shRNA 
resulted in 720 upregulated genes and 148 downregulated genes in the shMel18 mutant ES 
cells. PCGF2/MEL18 is a distinctive member of the canonical PRC1.2 complex which 
functions in the maintenance of gene repression in ES cells and also plays essential roles during 
the early mesoderm precursor formation from mouse ES cells (Morey et al., 2015). To 
understand the mechanism of downregulation of target genes upon compromised expression of 
polycomb proteins has been of significant interest lately (Gao et al., 2014). Recently, the RYBP 
containing ncPRC1.3 and ncPRC1.5 complexes were identified to activate genes related to 
autism in the CNS by interacting with newly identified interacting partners AUTS2 and CK2 
(Figure 5) (Gao et al., 2014). 
Previously our group reported that compromised expression of RYBP leads to severe 
alterations in the expression of many genes essential for cardiac differentiation in the mutant 
cells (Figure 15) (Ujhelly et al., 2015). Several cardiac transcription factors such as Isl1, Tbx5 
and Tnnt2 express at reduced mRNA levels in the Rybp null mutant CMCs (Figure 16). One of 
the most downregulated genes was Plagl1, which was of utmost interest to us since PLAGL1 
is a key cardiac transcription factor (Yuasa et al., 2010). PLAGL1 can bind at critical cardiac 
gene loci, such as Nkx2-5, Tropomyosin 2 (Tpm2), Plectin (Plec) and Myosin heavy chain 7B 
(Myh7b) identified by ChIP-seq assay in N2A cells (Varrault et al., 2017).  
In the current study, we provide evidence that Plagl1 is not expressed in the Rybp-/- cells neither 
in mRNA nor at protein levels during any stages of in vitro cardiac differentiation. Based on 
our results we hypothesized that Plagl1 might be a downstream target of RYBP. To examine 
this hypothesis, we first tried to understand the complex regulatory regions of Plagl1 
 91 
expression. We dissected the Plagl1 genomic locus, described all splice variants and the coded 
protein products in detail. The Plagl1 genomic locus has had many schematic illustrations 
updated several times. The original description of the Plagl1 locus showed that Plagl1 had 8 
exons with one promoter region (P1 promoter). The P1 promoter resides upstream to exon 4 
containing a conserved CpG island which is also present in rat and human PLAGL1 (Figure 
19) (Smith et al., 2002). Later Valleley and colleagues (Valleley et al., 2010) identified a second 
promoter region, which they termed as P2 situated 30 kb upstream to the previously described 
P1 promoter. The P2 promoter has an unmethylated CpG island which can produce biallelic 
expression of Plagl1 in leukocytes and pancreas during disease condition such as TNDM. 
Another independent study about the Plagl1 genomic locus showed that Plagl1 had 9 exons 
with a 3 kb promoter region upstream to exon 4 (P1 promoter) that can be activated by cardiac 
transcription factor NKX2-5 (Yuasa et al., 2010). Next, demonstrating that MEF2C can 
regulate Plagl1 expression in rat mesenchymal cells (Czubryt et al., 2010), identified a novel 
5.4 kb alternate promoter region (P3 promoter) containing a MEF2C consensus site 
immediately upstream to the exon 10 by in silico analysis. The latest illustration of the mouse 
Plagl1 locus gave the most detailed description of the promoters and the presence of the two 
ncRNAs Hymai and Plagl1it (Platas et al., 2012). By performing 5’ and 3’ RACE along with 
EST analysis the position of the transcripts was mapped from the three different promoter 
regions which were described previously naming them as P1, P2 and P3 promoters (Platas et 
al., 2012). In our study, we further verified the positions of the exons, promoters, regulatory 
elements and the ncRNAs Hymai and Plagl1it ncRNAs. Our schematic illustration of the 
Plagl1 locus is an updated depiction from all previously available data (Figure 19). We also 
provide novel information about the promoters potentially active during cardiac development 
as previous studies only aimed at characterizing the promoters and elucidating imprinting at 
the genomic locus. We performed gene expression analysis using exon specific primers Plagl1 
1/2, Plagl1 6/7, and Plagl1 10/11 to validate which promoter were producing protein coding 
transcripts during in vitro cardiac differentiation. Our results suggested that only the P1 and P3 
promoters are active during cardiac differentiation (Figure 22). This data further strengthens 
the theory that the Plagl1 P2 promoter is only active and produces biallelic expression of 
Plagl1 in specific tissues such as leukocytes and pancreas during disease states such as TNDM.  
PLAGL1 protein was previously identified to express abundantly in the embryonic heart in a 
chamber restricted pattern (Yuasa et al., 2010). Present study provides novel information 
characterizing the expression of PLAGL1 during in vitro differentiation of ES cells into cardiac 
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lineage. In the wild type cultures, Plagl1 expression was not observed at day 0 and day 2 
indicating that PLAGL1 may not have any role in maintaining the pluripotency of ES cells and 
in consequent germ layer formation (Figure 18). PLAGL1 expression was first detectable at 
day 4, which is a very early stage when the cardiac progenitors form indicating its role in early 
lineage commitments. Our gene expression analyses and co-expression of RYBP and PLAGL1 
in the differentiating cells raised our hypothesis that Plagl1 could be a downstream target of 
RYBP during cardiac morphogenesis (Figure 26). 
By performing luciferase reporter assay we have examined the role of RYBP in regulating 
Plagl1 at the promoter levels, and we determined that RYBP activates the P1 and P3 promoters. 
In order to clarify the mechanism by which RYBP activated the Plagl1 promoters we 
demonstrated that RYBP activates both P1 and P3 promoter in a polycomb independent 
manner (Figure 29, 30 and 31). By performing similar promoter activity assays using RYBP in 
combination with E2F (E2F2 and E2F3) and YY1 transcription factors we also determined that 
the activation of the Plagl1 promoters by RYBP differs from the previously identified 
activation mechanisms by RYBP (Figure 33).  
Several ncRNAs have been identified to play vital roles in cellular processes including 
chromatin remodelling, DNA repair and translation (Wang & Chang, 2011). The recent 
development in the ncRNAs have increased the interest in identifying the interactions and 
functions of ncRNA. Several ncRNAs have been already identified in the polycomb mediated 
regulation of genes. Inactive X specific transcripts (Xist), Braveheart (Bvht), and Maternally 
expressed gene 3 (Meg3) are some of the many ncRNAs identified to interact with polycomb 
complex proteins (Bousard et al., 2019; Klattenhoff et al., 2013; Sunwoo et al., 2015; Wu et 
al., 2018). Xist mediates whole chromosome transcriptional silencing during the dose 
compensation process in mammals (Sahakyan et al., 2018). Bvht and Meg3 are determined to 
likely induce cardiac lineage commitment and are expressed upstream to Mesp1, potentiate to 
regulate a core cardiac gene network (Klattenhoff et al., 2013; Wu et al., 2018).  
Hymai and Plagl1it ncRNAs are both imprinted and express only from one allele from the 
Plagl1 genomic locus (Benedetti et al., 2017). The expression of Hymai is partially connected 
to the expression of Plagl1 since Hymai is also transcribed upon the regulation of P1 promoter 
and altered expression of both PLAGL1 and Hymai are indicative of disease condition such as 
TNDM and tumors. Plagl1it ncRNA was identified from independent RACE experiments 
(Platas et al., 2012). Although few studies have described the functions of Hymai, not much is 
known about Plagl1it. From our expression studies by qRT-PCR we also determined the 
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altered expression pattern of the ncRNAs Hymai and Plagl1it in the Rybp null mutant cultures 
during in vitro cardiac differentiation (Figure 20). High expression of the two ncRNAs at day 
14 of wild type cardiac differentiation CMCs shows that the ncRNAs might function during 
the terminal stages of CMC formation (Figure 20). Therefore, we were keen to investigate 
whether Hymai and Plagl1it affected the activation of Plagl1 by RYBP. Our results determined 
that the two ncRNAs could activate the Plagl1 P1 and P3 promoters themselves. But the 
overexpression of either Hymai or Plagl1it did not alter the activity of the Plagl1 promoters 
regulated by RYBP (Figure 34).  
To identify the mechanism by which RYBP can activate Plagl1 expression, we subcloned the 
P3 promoter as various smaller fragments and determined their inducibility by RYBP. By 
combining the acquired results with TFBS we demonstrated that consensus binding sites for 
cardiac progenitor transcription factors Nkx2-5 and Mef2c was required for the activation of 
the P3 promoter by RYBP (Figure 35). Two previous studies have shown that Nkx2-5 and 
Mef2c can activate the expression of Plagl1. (Czubryt et al., 2010; Yuasa et al., 2010). By 
performing site directed mutagenesis of the Nkx2-5 and Mef2c consensus sites we confirmed 
that the Nkx2-5 consensus site was indeed essential for the activation of the P3 by RYBP 
(Figure 36). 
By combining Co-IP and ChIP-qRT-PCR methods we also proved that RYBP interacts with 
NKX2-5 protein (Figure 37) and this interaction is vital in the regulation of Plagl1 in the wild 
type CMCs. RYBP is bound at the Nkx2-5 consensus sites in both P1 and P3 promoters in d7 
CMCs and not in d0 ES cells where Plagl1 is normally expressed (Figure 38). Since Nkx2-5 
only expressed after cardiac lineage commitment and vital for the progenitor formation, these 
results nicely recapitulate the expression kinetics of Plagl1 during cardiac differentiation. Our 
results also indicate a potential interaction of Hymai and Plagl1it with NKX2-5 as they 
increased the fold activation levels of the P3 promoter by NKX2-5 extensively (Figure 40). 
Our results also suggest that although aberrant expression of Nkx2-5, Hymai and Plagl1it in 
the Rybp null mutant CMCs could itself impact Plagl1 regulation, the consequence of the 
absence of Rybp might result in a more several decline in the activation of Plagl1 (Figure 20). 
Since Plagl1 expression was not detected neither at mRNA nor at protein levels in the Rybp 
null mutant cultures, the loss of Plagl1 functions could at least partially contribute to the 
phenotype of the Rybp null mutant CMCS during cardiac differentiation. Rybp null mutant 
CMCs lack proper sarcomere formation and subsequent contractility (Figure 16) (Henry et al., 
2020). Therefore, to examine whether Plagl1 expression is important for sarcomere formation, 
 94 
we determined the colocalization of PLAGL1 and a sarcomere marker CTNT by ICC. We 
found that PLAGL1 expression was profoundly present in the CTNT positive cells, suggesting 
that PLAGL1 preferentially expressed in cells differentiating towards terminal CMCs. 
Luciferase reporter assays showed that Plagl1 can activate the expression of Tnnt2 promoter. 
These data together provide vital understanding about the role of Plagl1 in CMC formation 
and the molecular mechanism by which RYBP functions during cardiac morphogenesis (Figure 
43 and 44).  
 
Figure 44: Model of in vitro cardiac differentiation in the presence and absence of Rybp 
(A) Differentiation of wild type ES cells towards CMCs in the presence of Rybp. The expression 
of key cardiac transcription factors such as NKX2-5, MEF2C and TBX5 guide cardiac lineage 
commitment and differentiation. In the wild type, RYBP interacts with NKX2-5 to activate 
Plagl1 expression associating with Hymai and Plagl1it. PLAGL1 activates Tnnt2 expression 
via its promoter and thereby affects sarcomere formation. 
(B) Differentiation of pluripotent ES cells towards CMCs is impaired in the absence of Rybp. 
During cardiac differentiation progenitor transcription factors (Nkx2-5, Mef2c and Tbx5) 
exhibit reduced expression levels in the Rybp null mutants. Moreover, in the absence of Rybp, 
Plagl1 expression is absent, which also affects sarcomere formation. As a result, the formation 
of terminally differentiated cardiomyocytes is impaired and contractility is compromised in the 





























































Taken together our results provide vital novel information about the regulatory functions of 
RYBP during cardiac development. We propose that RYBP acts by activating specific cardiac 
genes via Plagl1 (Figure 44). The interaction between RYBP and NKX2-5 protein is a novel 
finding, and these results broadens the understanding about the alliance between polycomb 
proteins and lineage specific markers to regulate differentiation. Overall, these results also 
affirm the theory that in certain cases polycomb proteins, such as RYBP could also exert their 
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8. SUMMARY OF THE PHD THESIS 
INTRODUCTION 
In my PhD study, I have focused on the functions of a PcG protein RYBP, during the early 
onset of cardiac development using mouse ES cells based in vitro differentiation system. We 
have earlier shown that RYBP is expressed in the mouse developing heart in vivo and that ES 
cells lacking RYBP could not form functionally contracting CMCs in vitro. In my PhD thesis, 
I have further dissected the underlying molecular mechanisms. Genome-wide transcriptomics 
using wild-type and Rybp null mutant CMCs revealed a list of genes with significantly altered 
expression in the Rybp null mutant CMCs including alterations in key mechanisms such as ion 
homeostasis, cell adhesion, cardiac progenitor formation and sarcomere organisation. One of 
the most downregulated gene in the Rybp null mutant CMCs was Pleiomorphic adenoma gene 
like 1 (Plagl1), a zinc finger protein with transactivation and consensus specific DNA-binding 
activities. Plagl1 is an essential factor for cardiac morphogenesis and is highly expressed in 
mouse hearts from E8.5 of embryonic development to adulthood in a chamber-restricted 
pattern. Importantly, ablation of Plagl1 in mouse embryos caused atrial and ventricular septum 
defects which often lead to cardiomyopathies. 
AIM 
To identify the regulatory mechanism that cause the downregulation of Plagl1 expression in 
the Rybp null mutant ES cells and CMCs and investigate how Plagl1 deficiency could 
contribute to the non-contractility phenotype of the Rybp null mutant CMCs.  
METHODS 
To achieve these aims I used wild-type and Rybp null mutant mouse ES cells and differentiated 
them to form cardiac cultures up to 21 days and have collected samples from day 0 
(pluripotent), day 2 (embryoid body), day 4 (early cardiac progenitor stage), day 7 and day 10 
(early CMCs), 14 and 21 (matured CMCs) for further assays. This included: (1) Gene 
expression studies using quantitative real-time polymerase chain reaction; (2) Western blot 
analyses to define protein content and kinetics; (3) Immunocytochemistry to determine the 
subcellular localization of PLAGL1 and its co-localization with key cardiac transcription 
factors such as cardiac CTNT.  
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RESULTS AND CONCLUSIONS 
Our results showed that PLAGL1 was first detected at the early progenitor formation stages 
(day 4) and the expression was the highest in the matured CMCs stage (day 14) of 
differentiation indicating its role in CMC formation. Since in the Rybp null mutant cultures, 
Plagl1 is not expressed at any time point of in vitro cardiac differentiation our current 
hypothesis is that cells lacking RYBP are impaired in their CMC development at least partially 
due to the impaired inducibility of Plagl1. 
Besides this, in silico analyses of the Plagl1 genomic locus has revealed that Plagl1 has a 
complex genomic structure containing 11 exons, 3 promoter regions (P1, P2 and P3) and 2 
ncRNAs Hymai and Plagl1it. From gene expression analyses using primers specific to the 
various splice variants of Plagl1, I determined that gene products from only Plagl1 P1 and P3 
promoters are transcribed during in vitro cardiac differentiation. Furthermore, the expression 
of the two ncRNAs Hymai and Plagl1it were also greatly altered in the Rybp mutant cells 
suggesting that every gene product from the entire Plagl1 locus is affected by the lack of Rybp 
in the mutant CMCs. Since the ncRNAs are transcribed from the same promoters as Plagl1 and 
were induced only at low level in the Rybp null mutant CMCs, suggested that RYBP may 
regulate the promoters of Plagl1. Therefore, I cloned the Plagl1 P1, P2 and P3 promoters into 
luciferase reporter constructs and performed reporter assays to investigate whether RYBP can 
regulate any of the Plagl1 promoters. My results revealed that RYBP can activate Plagl1 via 
the P1 and P3 promoters. By using truncated mutants of the P3 promoter, my experiments 
revealed that RYBP can activate the 3’ part of the P3 promoter that consisted of the TATA box 
and included consensus sites for cardiac transcription factors NKX2-5 and MEF2C. Site 
directed mutagenesis of the consensus sites of NKX2-5 and MEF2C and luciferase assays with 
RYBP disclosed that the NKX2-5 sites were essential for the activation of the P3 promoter by 
RYBP. ChIP-qRT-PCR analysis to determine if RYBP bound at the Plagl1 promoters revealed 
that RYBP bound at the NKX2-5 consensus in both the P1 and P3 promoter. Our results also 
determined that PLAGL1 co-expressed with CTNT in the wild type differentiating CMCs and 
PLAGL1 can activate Tnnt2 promoter. Since these transcription factors are required for the 
development of multiple cardiac cells types our results suggest that Plagl1 at least partially, 
mediates the effects of Rybp during cardiac differentiation. 
Taken together, my results provide novel interpretation on how the absence of RYBP can cause 
impairment in cardiac differentiation, which might also be relevant to disease conditions such 




A PhD tanulmányom középpontjában a polikomb csoportba tartozó RYBP fehérje szívizom 
irányú differenciációban betölött szerepének elemzése állt, melyet egér embrionális őssejteken 
alapuló in vitro differenciációs rendszerben vizsgáltunk. Vizsgálataink alapját azon korábbi 
megfigyelésünk képezte, hogy az RYBP termelődése egér szívben az embrionális fejlődés 
során kifejezett, továbbá hogy RYBP hiányában in vitro kultúrákban az őssejtek nem képesek 
funkcionálisan összehúzódó kardiomiocitákat (CMC) kialakítani. A doktori disszertációm 
során tovább elemeztem a molekuláris mechanizmusok hátterét. Először, Rybp null mutáns és 
vad típusú kardiális minták teljes genomi transzkriptom elemzését felhasználva kimutattunk 
egy sor olyan gént, amelynek expressziója szignifikánsan eltér az Rybp null mutáns 
szívizomsejtekben és olyan fő kardiális mechanizmusok résztvevői, mint pl. az ion 
homeosztázis, sejt adhézió, kardiális progenitor kialakítás és szarkomer organizáció. Az Rybp 
null mutáns szívizomsejtekben az egyik legkiugróbb változást egy DNS-kötő aktivitással 
rendelkező cink-ujj fehérje, a Pleiomorphic adenoma gene like 1 (Plagl1) mutatta. Ez a gén 
Rybp hiányában sem őssejtekben, sem pedig a CMC populációkban nem volt kimutatható. 
A Plagl1 a kardiális morfogenézis egyik nélkülözhetetlen tagja és a 8.5-ik naptól nagy 
mennyiségben termelődik a fejlődő egér szívkamrákban. Egér embrióban kimutatták, hogy 
Plagl1 hiányában a pitvari és kamrai válaszfal hibásan fejlődik ki, ami gyakran szívbetegségek 
kialakulásához vezet.  
 
CÉLKITŰZÉSEK 
Azonosítani a Plagl1 csökkent termelődésében szerepet játszó szabályozó 
mechanizmusokokat, Rybp null mutáns őssejtekben és kardiomiocitákban. Úgyszintén, 
megvizsgálni, hogy a hibás Plagl1 termelődés vajon miként játszhat szerepet az 
összehúzódásra képtelen Rybp null mutáns szívizomsejtek fenotípus kialakításában.  
 
MÓDSZEREK 
Céljaink megvalósításához, Rybp null mutáns és vad típusú egér őssejteket differenciáltattuk 
in vitro kardiális irányba. Az kolóniákat 21 napig növesztettük és az analízishez szükséges 
mintákat 0, 2, 4, 7, 10, 14, és 21 napokon gyűjtöttük be, ahol a nulladik nap a pluripotens, 2. 
 119 
nap az embrionális test, 4. nap a korai kardiális progenitor, a 7. és 10. nap a korai kardiomiocita 
a 14. és 21. nap pedig az érett kardiomiocita állapotot reprezentálja. Mintáink vizsgálatához a 
következő módszereket alkalmaztuk: (1) Kvantitatív valós idejű polimeráz lánc reakcióval 
(qRT-PCR) gén kifejeződést vizsgáltunk; (2) A fehérjék mennyiségének és kinetikájának 
kimutatásához Western-blot analízis alkalmaztunk; (3) Immunocitokémiai módszerekkel 
megvizsgáltuk a PLAGL1 sejteken belüli lokalizációját ill. hogy milyen más kulcsfontosságú 
kardiális transzkripciós faktorokkal mint pl. a kardiális troponinT-vel lokalizálódik együtt. (4) 
Luciferáz riporter próbával és helyspecifikus mutációs analízissel megvizsgáltuk az RYBP 
fehérje Plagl1 P1, P2 és P3 promóter szakaszára ill. a PLAGL1 fehérje kardiális troponinT 
promóterére kifejtett hatását, tehát hogy vajon transzkripcionálisan képes-e az RYBP a Plag1 
gén szabályozására.  
EREDMÉNYEK (ÉS KÖVETKEZTETÉSEK) 
Az eredmények rávilágítottak, hogy a PLAGL1 fehérje a korai kardiális progenitor 
kialakulásának stádiumában kezd el termelődni és a legnagyobb mértékű kifejeződést a 14. 
napon az érett kardiomiocita állapotban éri el, jelezve a PLAGL1 fontos szerepét a 
kardiomiociták kialakulásában. Az Rybp null mutáns szívizomtelepekben a Plagl1 egyik 
vizsgált időpontban sem mutatott expressziót ezért úgy véljük, hogy a Plagl1 hibás indukciója 
legalább részben felelőssé tehető a mutáns kolóniák rendellenesen fejlődő szívizomsejtjeinek 
kialakításában. Emellett in silico feltártuk a Plagl1 összetett genomi szerkezetét, ami 12 
exonból, 3 promóter régióból (P1, P2 és P3) és 2 nem-kódoló RNS-ből (Hymai és Plagl1it) 
áll. A különböző Plagl1 splice variánsok kimutatásához specifikus primereket terveztünk és 
gén expressziós analízissel kimutattuk, hogy in vitro kardiális differenciáció során csak a P1 
és P3 Plagl1 promóterek gén terméke íródik át. Továbbá a Hymai és Plagl1it nem kódoló RNS-
ek termelődése szintén változást mutatott az Rybp mutáns sejtekben, ez arra utal, hogy az Rybp 
hiánya a mutáns kardiomiocitákban hatással van a Plagl1 lokusz összes géntermékre. A nem 
kódoló RNS-eket ugyanazon promóter régiók szabályozzák, mint a Plagl1-et és csak kis 
mértékben indukálódtak az Rybp mutáns szívizomsejtekben, mindez arra engedtek 
következtetni, hogy az RYBP nagy valószínűséggel közvetlenül szabályozhatja a Plagl1 
promóterét. Ahhoz, hogy ezt a feltevésünket kísérletileg is alátámasszuk a P1, P2 és P3 Plagl1 
promótereket luciferáz riporter konstrukcióba klónoztuk. A riporter-assay eredményei 
feltárták, hogy az RYBP a P1 és P3 promótereken keresztül képes kifejteni aktiváló hatását. 
Ezután mutáns P3 promótereket hoztunk létre és segítségükkel kimutattuk, hogy az RYBP a 
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P3 promóter, TATA-boxokból valamint NKX2-5 és MEF2C kötő szekvenciákból álló, 3’ 
végét aktiválja. A konszenzus NKX2-5 és MEF2C szakaszok célzott mutagenezisével és 
RYBP luciferáz-assay segítségével megállapítottuk, hogy az Nkx2-5 kötő helyek megléte 
nélkülözhetetlen a P3 promóter aktiválásához. ChIP-qRT-PCR segítségével kimutattuk, hogy 
az RYBP képes kötődni az Nkx2-5 kötő konszenzus szekvenciához mindkét, P1 és P3, 
promóter esetében. Vad típusú kardiomiocitákon végzett kísérleteinkből az is kiderült, hogy a 
PLAGL1 ugyanazon sejtekben található mint a kariális troponinT és a PLAGL1 képes aktiválni 
a kardiális troponinT promóterét. Az előbb említett transzkripciós faktorok jelenléte több 
kardiális sejttípus kialakulásához is szükséges ezért az eredményeink arra engednek 
következtetni, hogy a kardiális differenciáció során a PLAGL1 legalább részben közvetíti az 
RYBP hatását. Összességében az eredményeink az RYBP hiányában fellépő hibás kardiális 
differenciáció új oldalait világítják meg, melyek a különböző kardiális betegségekben, mint pl. 
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